UNIT 2

CANCER

INTRODUCTION

Cancer is one of the most formidable health challenges of the modern era
and a significant component among lifestyle-related diseases. It is
characterized by the uncontrolled growth and spread of abnormal cells in the
body, which may result in death if not controlled. It is also called as a
malignant tumor, not every tumors are cancerous; benign tumors do not
extend to other part. Unlike acute infections, cancer often develops slowly and
is influenced by a combination of genetic, environmental, and—importantly—
lifestyle factors.

Modern lifestyle choices such as tobacco use, excessive alcohol

consumption, unhealthy dietary habits, physical inactivity, and chronic stress
have all been scientifically linked to the initiation and progression of various
cancers. Additionally, exposure to environmental carcinogens and occupational
hazards further exacerbates the risk. Lifestyle medicine therefore plays a vital
role in both the prevention and management of this disease.

Cancer is not a single disease but rather a group of more than 100
distinct conditions, each defined by the type of cell initially affected. Common
types covered in this unit include:

 Lung cancer
 Mouth (oral) cancer
 Skin cancer
 Cervical cancer
 Esophageal carcinoma
 Understanding the etiology of cancer involves exploring carcinogenic
triggers, with tobacco usage standing out as the leading preventable cause. In
fact, smoking is directly linked to cancers of the lungs, oral cavity, esophagus,
and more.

Recent advancements in diagnosis, such as the use of biomarkers,

imaging techniques, and screening methods like Pap smears or mammograms,
have significantly improved early detection rates. Likewise, treatment
strategies have evolved to include surgery, radiation therapy, chemotherapy,
immunotherapy, and targeted biological agents, offering hope for remission or
even cure in many cases.

This unit will comprehensively explore:

 The different types of cancer relevant to lifestyle factors

 Causes and risk factors, with emphasis on modifiable behaviors
 Modern diagnostic techniques including biomarkers
 Current and emerging treatment modalities

By the end of this unit, students will be able to critically analyze how
lifestyle behaviors influence cancer risk and the importance of early detection
and evidence-based management strategies in reducing its burden on public
health.

What is Cancer?

Definition:

Cancer is a complex group of diseases that result from uncontrolled

division of abnormal cells in the body. These cells not only grow
uncontrollably but also have the potential to invade surrounding tissues and
metastasize (spread) to distant organs via blood and lymphatic systems.
Unlike normal cells, cancerous cells ignore regulatory signals that control
growth, division, and apoptosis (programmed cell death).

Basic Biology of Cancer:

 Every cell in the human body is programmed to grow, perform a

function, and die in a regulated manner.
 In cancer, this program is disrupted due to accumulation of genetic
mutations that:
o Activate oncogenes: These genes promote cell division
excessively.
o Inactivate tumor suppressor genes: These normally control
growth or trigger cell death.
o Alter DNA repair mechanisms: Damaged DNA accumulates.
o Enable immortality: Cancer cells avoid death and divide
indefinitely.
o Promote angiogenesis: Cancer cells form new blood vessels to
nourish themselves.
o Facilitate metastasis: Cancer cells gain the ability to migrate to
other organs.

Benign Vs Malignant

 Tumors can be benign or malignant.

  Benign tumors can be removed and do not spread to other parts of the
body.

 Malignant tumors (cancer), on the other hand, often grow aggressively

locally where they start, but tumor cells also can enter into the
bloodstream or lymphatic system and then spread to other sites in the
body (metastasis).

What is Metastasis?

Metastasis is the spread of cancer cells from the original (primary)

site to distant organs or tissues in the body, where they form secondary
tumors. It is a key characteristic that differentiates malignant tumors from
benign tumors.

How Does Metastasis Occur?

Metastasis is a multi-step biological process involving:

1. Local Invasion
o Cancer cells break through the basement membrane of the tissue
where they originated.
2. Intravasation
o The cancer cells enter blood vessels or lymphatic vessels.
3. Circulation
o Cancer cells travel through the bloodstream or lymphatic
system, surviving the immune response and shear stress.
4. Extravasation
o They exit the vessels and move into new tissues (like lungs, liver,
bones, or brain).
5. Colonization
o Cancer cells adapt, survive, and multiply in the new location,
forming secondary tumors.
Important Characteristics of Metastasis:

 Metastatic tumors are made of cells from the primary tumor, not the
organ they spread to.
o Example: Lung cancer that spreads to the brain is still called
“metastatic lung cancer,” not brain cancer.
 Metastasis is a major cause of cancer death because it makes
treatment more complex and reduces the chances of cure.

Common Sites of Metastasis (Organ Preference):

Common Metastatic
Primary Cancer
Sites
Breast cancer Bone, lung, liver, brain
Lung cancer Brain, bone, liver
Prostate cancer Bone
Colorectal cancer Liver, lungs
Melanoma (skin cancer) Brain, lungs, liver
Classification of Cancer:

1. Broad/Classical Classification (by tissue type):

This is the standard academic classification used in pathology and

oncology:

Type What is it? Examples

Cancer arising from
Lung, breast, colon, prostate,
Carcinoma epithelial cells (lining of
skin, cervical, Mouth
organs, skin, glands)
Cancer arising from
connective tissues such Bone (osteosarcoma), cartilage,
Sarcoma
as bone, fat, cartilage, fat (liposarcoma)
muscle
 Cancer of blood-forming
Leukemia tissues (bone marrow, Acute lymphoblastic leukemia
WBCs)
Cancer of the lymphatic Hodgkin's lymphoma, non-
Lymphoma
system Hodgkin's lymphoma
Cancer of plasma cells in
Myeloma Multiple myeloma
the bone marrow
Cancers originating in
CNS cancers Glioblastoma, medulloblastoma
brain/spinal cord

2. Organ-Specific Classification (clinical types):

This is a practical and clinical way to refer to cancer based on the

location or organ where it occurs.

Belongs To This
Type Comments
Broad Class
Usually non-small cell or small
Lung cancer Carcinoma
cell carcinoma
Often squamous cell carcinoma
Mouth cancer Carcinoma
of oral mucosa
Includes basal cell, squamous
Skin cancer Carcinoma
cell, and melanoma
Squamous cell carcinoma or
Cervical cancer Carcinoma
adenocarcinoma
Esophageal Squamous cell or
Carcinoma
carcinoma adenocarcinoma types
What Causes Cancer?

Cancer is multifactorial. It develops due to a combination of genetic

predisposition, environmental exposures, biological infections, and
lifestyle factors. These factors contribute to genetic mutations that transform
normal cells into malignant ones.

Genetic Factors:

 Some individuals are hereditarily predisposed to cancer due to

inherited mutations.
 Examples:
o BRCA1/BRCA2 mutations increase the risk of breast and ovarian
cancers.
o Lynch Syndrome (HNPCC) increases the risk of colorectal, uterine
cancers.
o TP53 gene mutations (Li-Fraumeni Syndrome) are associated
with a wide range of cancers at a young age.

However, genetic predisposition alone rarely causes cancer—it acts in synergy

with environmental and lifestyle factors.

2.2 Lifestyle and Environmental Causes:

A. Tobacco Use:

 Most preventable cause of cancer globally.

 Contains over 7000 chemicals; at least 70 are known carcinogens
including benzo[a]pyrene, arsenic, formaldehyde, polonium-210, and
nitrosamines.
 Causes cancers of:
o Lung
o Oral cavity and pharynx
 o Esophagus
o Pancreas
o Kidney
o Bladder
o Cervix
 Smoking cessation reduces cancer risk drastically—even in long-term
smokers.

B. Alcohol Consumption:

 Alcohol metabolizes into acetaldehyde, a known carcinogen.

 Damages DNA, promotes inflammation, and increases estrogen levels
(risk factor for breast cancer).
 Increases risk of:
o Liver cancer
o Oral and pharyngeal cancers
o Esophageal cancer
o Breast cancer
o Colorectal cancer

C. Diet and Nutrition:

 High intake of red/processed meats (e.g., bacon, sausages) linked to

colorectal cancer.
 Low fiber intake impairs digestion and bowel health.
 High sugar and fat intake contribute to obesity, a major risk factor for
cancer.
 Protective foods include: cruciferous vegetables, berries, omega-3 fatty
acids.
D. Physical Inactivity and Obesity:

 Obesity increases chronic inflammation and insulin resistance, both of

which promote cancer growth.
 Associated with higher incidence of:
o Postmenopausal breast cancer
o Endometrial cancer
o Colorectal cancer
o Pancreatic cancer
 Exercise helps regulate hormones and improves immune surveillance.

E. Infectious Agents:

Infectious Agent Associated Cancer

HPV (Human Papillomavirus) Cervical, anal, oropharyngeal cancers
Hepatocellular carcinoma (liver
Hepatitis B and C
cancer)
Nasopharyngeal carcinoma, Burkitt’s
Epstein-Barr Virus
lymphoma
H. pylori Gastric cancer

Vaccination and eradication therapies help prevent such cancers.

F. Radiation Exposure:

 Ionizing radiation (X-rays, gamma rays): DNA breaks → leukemia,

thyroid cancer.
 Ultraviolet (UV) radiation: Primarily causes skin cancers (basal cell,
squamous cell, melanoma).
 Protective measures: Sunscreens, avoiding tanning beds, using shielding
in medical imaging.

G. Occupational and Environmental Exposure:

  Asbestos → Mesothelioma
 Benzene → Leukemia
 Vinyl chloride → Liver cancer
 Arsenic-contaminated water → Skin and bladder cancers

Signs and Symptoms of Cancer

Cancer symptoms vary widely depending on the type, stage, and location.
However, certain general signs may signal malignancy.

General Symptoms (Systemic):

 Unexplained weight loss: Losing ≥10% of body weight without dieting.

 Persistent fatigue: Not relieved by rest; due to cancer cells consuming
nutrients.
 Fever or night sweats: Especially in leukemia and lymphomas.
 Loss of appetite: Often early sign in gastrointestinal cancers.
 Pain: Persistent, progressive pain may suggest advanced disease.

Localized Symptoms (By Organ System):

System/Organ Common Symptoms Potential Cancers

Chronic cough, chest
Respiratory Lung cancer
pain, hemoptysis
Difficulty swallowing,
Esophageal, stomach,
Digestive blood in stool, persistent
colorectal
indigestion
Abnormal vaginal
Reproductive (female) Cervical, endometrial
bleeding, pelvic pain
Non-healing ulcers,
Oral cavity Oral, tongue cancer
difficulty chewing
Skin Change in mole (ABCDE Melanoma, BCC
 rule), bleeding sore
Painless enlarged lymph
Lymphatic Lymphoma
nodes
Blood in urine, painful
Urinary Bladder, kidney cancer
urination

Paraneoplastic Syndromes:

These are indirect effects of cancer unrelated to local tumor invasion or

metastasis:

 Hypercalcemia: Often due to secretion of PTHrP (parathyroid hormone-

related protein) by tumors.
 Cushing’s syndrome: Due to ectopic ACTH secretion.
 SIADH (Syndrome of Inappropriate Antidiuretic Hormone): Seen in
small-cell lung cancer.

CAUTION Acronym (Cancer Warning Signs by ACS):

 C – Change in bowel or bladder habits

 A – A sore that does not heal
 U – Unusual bleeding or discharge
 T – Thickening or lump
 I – Indigestion or difficulty swallowing
 O – Obvious change in wart or mole
 N – Nagging cough or hoarseness

Early detection of these signs can be life-saving.

Cancer Prevention

Cancer is largely a preventable disease. According to WHO and the

American Cancer Society, at least 30–50% of all cancers can be prevented by
modifying or avoiding key risk factors. Prevention strategies include lifestyle
modifications, vaccinations, early screening, and environmental
protection.

1. Primary Prevention: Avoiding Risk Factors

1.1 Tobacco Control

 Tobacco is the single most preventable cause of cancer.

 Responsible for:
o 85–90% of lung cancers
o Oral, esophageal, bladder, pancreatic, cervical cancers
 Prevention measures:
o Complete cessation of smoking and tobacco chewing
o Avoid secondhand smoke (passive smoking)
o Public health laws: smoking bans, cigarette taxation, anti-tobacco
campaigns

1.2 Healthy Diet and Nutrition

 Eat a balanced diet rich in:

o Fruits, vegetables, whole grains, fiber
o Foods rich in antioxidants (vitamins A, C, E)
 Limit:
o Red and processed meats
o Excessive salt and sugar
o Saturated and trans fats
 Rationale: A healthy diet helps prevent obesity, supports immunity, and
reduces exposure to dietary carcinogens (e.g., nitrosamines in processed
meat)
1.3 Physical Activity

 At least 150 minutes of moderate exercise per week recommended by

WHO
 Reduces risk of colon, breast, endometrial, and pancreatic cancers
 Regulates hormones (e.g., insulin, estrogen), lowers inflammation, and
supports healthy weight

1.4 Alcohol Moderation

 Alcohol is a Group 1 carcinogen (IARC classification)

 Increases risk of:
o Oral, pharyngeal, laryngeal, liver, breast, and colorectal cancers
 Prevention:
o Limit or avoid alcohol intake
o Educate public on alcohol–cancer connection

1.5 Protection from UV Radiation

 UV exposure causes:
o Basal cell carcinoma (BCC)
o Squamous cell carcinoma (SCC)
o Melanoma
 Preventive steps:
o Use broad-spectrum sunscreens (SPF 30+)
o Wear protective clothing, hats, sunglasses
o Avoid tanning beds and midday sun (10 AM–4 PM)

1.6 Avoidance of Occupational and Environmental Carcinogens

 Examples: asbestos, benzene, radon gas, arsenic

 Workers in high-risk industries must use:
o Personal protective equipment (PPE)
 o Workplace ventilation
o Regular health check-ups and occupational safety standards

2. Secondary Prevention: Early Detection and Screening

2.1 Regular Screening Tests

Screening tests are conducted to detect cancer or pre-cancerous
changes at an early, treatable stage, especially before symptoms appear.
The goal is to reduce cancer mortality through timely intervention.

Recommended
Cancer Type Screening Test
Age/Group
Women aged 21 to 65
Cervical Cancer - Pap smear- HPV DNA testing
years
Women aged 40 years
- Mammography (X-ray of breast
Breast Cancer and above (every 1–2
tissue)
years)
- Colonoscopy- FIT (Fecal
Colorectal Adults aged 45 years
Immunochemical Test)-
Cancer and above
Sigmoidoscopy
- Visual oral examination by a Especially for tobacco or
Oral Cancer
dentist/doctor alcohol users
- PSA (Prostate-Specific Antigen) Men aged 50 years and
Prostate Cancer blood test- DRE (Digital Rectal above, or earlier if high
Examination) risk

2.2 Health Education

 Awareness campaigns on signs and symptoms

 Importance of regular check-ups
 Encouraging self-exams (e.g., breast self-exam)
3. Tertiary Prevention: Prevent Recurrence or Complications

 For diagnosed patients:

o Adherence to treatment
o Lifestyle modifications to prevent recurrence
o Regular follow-up and rehabilitation
o Psycho-oncology support

4. Immunization (Cancer Vaccines)

4.1 HPV Vaccine

 Prevents infection with high-risk HPV types (16, 18)

 Reduces risk of:
o Cervical cancer
o Anal, penile, oropharyngeal cancers
 Recommended for:
o Girls and boys aged 9–14 (before sexual debut)
o Also available for adults up to age 26

4.2 Hepatitis B Vaccine

 Prevents chronic HBV infection → prevents liver cancer

 Given as part of universal childhood immunization
 High-risk adults (healthcare workers, IV drug users) should also be
vaccinated

5. Psychological and Emotional Well-Being

 Chronic stress and depression can impair immunity and increase

inflammatory markers
 Practices like:
o Mindfulness
 o Yoga and meditation
o Social support
o Mental health counseling
 Help in reducing cancer risk and improving outcomes

6. Community and Policy-Level Interventions

 Implementation of national cancer control programs

 Anti-tobacco legislation (e.g., Cigarettes and Other Tobacco Products Act
– COTPA in India)
 Urban planning for walkable cities to promote physical activity
 Subsidies for healthy foods, bans on carcinogenic substances

Cancer Staging

What is Cancer Staging?

Staging is the process of determining the extent of cancer in the body,

including:

 The size of the primary tumor,

 Whether the cancer has spread to nearby lymph nodes,
 Whether it has metastasized (spread to distant organs).

Staging is essential for:

 Determining prognosis,
 Guiding treatment decisions,
 Comparing treatment outcomes across patients and studies,
 Enrolling in appropriate clinical trials.
The TNM Staging System

The TNM system, developed by the American Joint Committee on

Cancer (AJCC) and the Union for International Cancer Control (UICC), is
the most widely used cancer staging method.

TNM stands for:

Code Meaning Evaluates

Size and local extent of the primary
T Tumor
tumor
Involvement of regional lymph
N Node
nodes
Presence or absence of distant
M Metastasis
metastasis

Each component is assigned a numerical value to describe the severity

1. T – Primary Tumor

 Describes tumor thickness, invasion depth, and presence of

ulceration (particularly in melanoma).
 Usually ranges from Tis (carcinoma in situ) to T4 (large or deeply
invasive).

For Melanoma (8th Edition AJCC):

 Melanoma staging primarily relies on Breslow thickness, measured in

millimeters (mm), and the presence or absence of ulceration.

Breslow
T Stage Ulceration Subclassification
Thickness
Tis In situ No Confined to epidermis only
 T1a = no ulceration; T1b = with
T1 ≤1.0 mm Yes/No
ulceration or high mitotic rate
T2 1.01–2.0 mm Yes/No T2a/T2b
T3 2.01–4.0 mm Yes/No T3a/T3b
Yes (a) /No
T4 >4.0 mm T4a/T4b
(b)

Breslow Depth is the most critical predictor of prognosis in melanoma.

For Squamous Cell Carcinoma (SCC):

For cutaneous SCC, T staging considers:

 Tumor size
 Depth of invasion
 Perineural invasion
 Location
 Poor differentiation

T Stage Description
Tis Carcinoma in situ (Bowen’s disease)
T1 ≤2 cm, no high-risk features
>2 cm or high-risk features (e.g., depth >6 mm, poor
T2
differentiation, perineural invasion)
T3 Invasion into bone or extensive perineural invasion
T4 Invasion into axial skeleton or skull base

For Basal Cell Carcinoma (BCC)

Although most BCCs are not formally staged due to their low metastatic
risk, advanced or aggressive BCCs may use similar T staging:
  Tumor size >2 cm
 Invasion into deep structures (bone, cartilage, muscle)
 Perineural invasion

2. N – REGIONAL LYMPH NODES

The N category assesses the presence, number, size, and extent of

lymph node involvement.

MELANOMA – N CATEGORY

N Stage Nodes Involved Characteristics

No nodal
N0 None
metastasis
1 node or in-transit/satellite metastasis
N1
without nodes
2–3 nodes or a combination with in-transit
N2
lesions
≥4 nodes, matted nodes, or in-transit
N3
metastasis with nodal involvement

Micrometastasis (found only on sentinel node biopsy) is distinguished

from macrometastasis (clinically apparent or radiologically evident).

SCC – N CATEGORY

N Stage Description
N0 No nodal metastasis
N1 Single node ≤3 cm
Single >3 cm but ≤6 cm or multiple
N2
nodes ≤6 cm
N3 Any node >6 cm or with extracapsular
 spread

Extracapsular extension significantly worsens prognosis.

3. M – DISTANT METASTASIS

The M category defines whether the tumor has spread to organs distant
from the primary site, such as the lungs, liver, brain, or bone.

MELANOMA – M CATEGORY

M Stage Site of Metastasis Serum LDH

M0 No distant spread Normal
Skin, subcutaneous, or distant
M1a Normal
lymph nodes
M1b Lungs Normal
M1c Other visceral sites Normal
M1d CNS (e.g., brain) Any level
Mx Metastasis cannot be assessed —

Elevated LDH (lactate dehydrogenase) indicates worse prognosis in M1

disease.

SCC – M CATEGORY

M Stage Description
M0 No distant metastasis
M1 Distant metastasis present (rare)

STAGE GROUPING – MELANOMA

Combining T, N, and M values gives us Stage 0 to Stage IV:

Stage Description
 Stage 0 Tis, N0, M0 (in situ)
Thin tumor ≤2 mm, no nodes or
Stage I ulceration (or) Tumor is small &
localized, no lymph node involvement
Stage II Thicker tumor >2 mm or with ulceration
Stage Any tumor with nodal or in-transit
III spread
Stage
Any tumor with distant metastasis
IV

Other Important Staging Concepts

1. Breslow Thickness (Melanoma only)

 Measured from the top of the granular layer to the deepest point of
invasion.
 Strongest predictor of survival:
o <1 mm → Excellent prognosis
o 4 mm → Poorer prognosis

2. Clark Level (now obsolete for staging)

 Describes anatomic level of invasion:

o Level I: Epidermis (in situ)
o Level II: Into papillary dermis
 o Level III: Fills papillary dermis
o Level IV: Into reticular dermis
o Level V: Into subcutaneous fat

3. Ulceration

 Loss of epidermis above tumor.

 Associated with higher grade and worsens stage (e.g., T2a → T2b).

4. Mitotic Rate

 Number of mitoses per mm².

 Used in some staging systems as a marker of aggressiveness.

5. In-Transit/Satellite Metastasis

 Tumor deposits in skin or subcutaneous tissue between primary lesion

and regional lymph node.
 Associated with Stage III melanoma.

Clinical Utility of Staging

Application Use

Prognosis Higher stage → lower survival

Treatment Stage I–II: surgery; Stage III–IV: systemic therapy

Higher stages need more frequent imaging and clinical

Follow-up
surveillance

Trials Stratify patients for research and drug development

Types of Cancer:

Lung Cancer:
 Lung cancer is the 2nd most common cancer worldwide. It is the most
common cancer in men and the 4th most common cancer in women. There were
more than 2.2 million new cases of lung cancer in 2020. Smoking is the leading
cause of this type of cancer, responsible for approximately 85% of all cases.
Lung cancer is often diagnosed at advanced stages when treatment options are
limited.

Anatomy of the Lungs

The lungs are a pair of vital, spongy, cone-shaped organs located in the
thoracic (chest) cavity, responsible for gas exchange—supplying oxygen to
the blood and removing carbon dioxide. Normal respiration begins by inhaling
air through mouth and nose. This air flows down into the trachea, that divides
into the left and right bronchi, and then to the alveoli. The alveoli are
responsible for oxygenating the blood for circulation as well as removing CO2
from the blood.

1. Gross Anatomy:

a) Location and Structure

 The lungs are seen in the intrathoracic space, which is filled by the
mediastinum. It corresponds to the connective tissue space which has
the heart, vital blood vessels, the trachea with the bronchi, the
esophagus and the thymus gland.
 Right Lung: Has three lobes – upper (superior), middle, and lower
(inferior).
 Left Lung: Has two lobes – upper and lower – with a cardiac notch to
accommodate the heart.
b) Pleura

 Each lung is surrounded by a double-layered membrane:

o Visceral pleura: Adheres to the lung surface.
o Parietal pleura: Lines the thoracic cavity.
o Between them is pleural fluid, which reduces friction during
breathing.

c) Bronchial Tree

 Trachea (windpipe) divides into:

o Right and left main bronchi (trachea at its lower end divides into
an inverted Y-shaped two main bronchi)
o Then into lobar bronchi (one for each lobe)
o Then into segmental bronchi, which further branch into:
 Bronchioles → Terminal bronchioles → Respiratory
bronchioles → Alveolar ducts → Alveoli
 Alveoli are tiny sacs where gas exchange occurs.

2. Blood Supply

 Pulmonary arteries: Carry deoxygenated blood from the heart to lungs.

 Pulmonary veins: Carry oxygenated blood back to the heart.
  Bronchial arteries: Supply oxygen-rich blood to lung tissue itself.

3. Histology of the Lungs (Microscopic Structure)

The microscopic structure of the lungs reflects its primary function —

gas exchange — and is composed of different types of epithelial cells
depending on the location within the respiratory tract.

Respiratory Epithelium: A Gradual Transition

As air travels from the trachea down to the alveoli, the epithelial lining
changes to meet the functional needs of each region.

Location Epithelium Type Function

Ciliated - Mucus production- Traps
pseudostratified dust/pathogens- Cilia move
Trachea & Bronchi
columnar epithelium mucus upwards toward the
with goblet cells throat (mucociliary escalator)
Bronchioles Simple - Less mucus- Transition
 columnar/cuboidal zone to respiratory portion
epithelium, fewer goblet
cells
- Optimized for efficient gas
Simple squamous
Alveoli diffusion between air and
epithelium (very thin)
blood

Alveoli – Site of Gas Exchange

Alveoli are tiny air sacs (millions per lung) where oxygen enters the
blood and carbon dioxide exits. Their walls are extremely thin (only one cell
thick), allowing gases to diffuse quickly across them.

Two Key Cell Types in Alveolar Walls:

1. Type I Pneumocytes (Type I Alveolar Cells)

 Shape: Thin, flat cells that resemble fried eggs

 Cover ~95% of the alveolar surface area
 Function:
o Facilitate gas exchange (O₂ and CO₂) between the alveoli and
pulmonary capillaries
o Form the structural base of the blood-air barrier
 Features:
o Extremely thin cytoplasm (<0.2 μm) reduces diffusion distance
o Non-dividing; damaged Type I cells are replaced by Type II cells

2. Type II Pneumocytes (Type II Alveolar Cells)

 Shape: Cuboidal and more rounded

 Cover ~5% of alveolar surface but are more numerous than Type I cells
 Function:
o Secrete pulmonary surfactant, a lipoprotein-rich substance that:
  Reduces surface tension in the alveoli
 Prevents alveolar collapse during exhalation
o Serve as progenitor cells — can divide and differentiate into Type
I cells during repair

Cell Type Location Function

Type I Pneumocytes Alveolar wall Gas exchange
Surfactant secretion;
Type II Pneumocytes Alveolar wall Regeneration of Type I
cells

Clinical Importance:

 Surfactant deficiency (e.g., in premature infants) leads to Neonatal

Respiratory Distress Syndrome (NRDS) — alveoli collapse due to
surface tension.
 Inhalation of toxins or infections (like COVID-19) can damage Type I
and II cells, impairing gas exchange and surfactant production.

How Lung Cancer Develops

Lung cancer develops when cells in the lungs mutate and begin to
divide uncontrollably, forming a malignant tumor. It primarily arises in the
epithelium lining the bronchi and bronchioles.

Pathogenesis (How It Begins and Progresses):

1. Initiation:
o Chronic exposure to carcinogens (like tobacco smoke) causes DNA
damage.
o Mutations in tumor suppressor genes (e.g., TP53) and activation of
oncogenes (e.g., KRAS) initiate cancerous changes.
2. Dysplasia:
 o Cells undergo premalignant changes; abnormal cells appear in
bronchial lining (often called bronchial dysplasia or carcinoma in
situ).
3. Invasion:
o Cancer cells break through the basement membrane and invade
underlying tissues.
4. Tumor Formation:
o A visible mass or nodule forms, commonly detected on chest X-
rays or CT scans.
5. Metastasis:
o Cancer spreads to lymph nodes, brain, liver, bones, or adrenal
glands via blood or lymph.

Types of Lung Cancer

Lung cancer is broadly categorized based on the histological

appearance of tumor cells under a microscope. The two main types are:

1. NON-SMALL CELL LUNG CANCER (NSCLC)

What is NSCLC?
 Non-Small Cell Lung Cancer (NSCLC) refers to a group of lung cancers
that behave in a clinically similar way and are not small cell in nature under
the microscope. NSCLC is the most common form of lung cancer, making up
about 85–90% of all cases.

It arises from normal bronchial epithelial cells that have acquired

multiple genetic lesions.

Unlike Small Cell Lung Cancer, NSCLC tends to grow and spread more
slowly, and is often more amenable to surgical treatment when detected
early.

Subtypes of NSCLC:

1 Adenocarcinoma

 Definition: A cancer that originates from glandular epithelial cells of

the lung, particularly those that produce mucus.
 Location: Usually found in the peripheral (outer) regions of the lung.
 Common in:
o Non-smokers
o Women
o Younger patients
 Histology:
o Cells with mucin production
o May form glandular structures under microscope
 Molecular Mutations:
o Often associated with EGFR, ALK, ROS1, KRAS mutations.
 Clinical Features:
o Persistent dry cough, fatigue, weight loss.
o Can present late due to peripheral location.
 Treatment:
 o Surgical resection in early stages.
o Targeted therapies for EGFR/ALK-positive tumors.
o Chemotherapy/radiotherapy in advanced stages.

2 Squamous Cell Carcinoma

 Definition: A cancer arising from squamous epithelial cells lining the

bronchial tubes.
 Location: Commonly located in the central part of the lungs near large
airways (bronchi).
 Strongly associated with: Cigarette smoking.
 Histology:
o Keratin pearls and intercellular bridges under light microscopy.
 Clinical Features:
o Early symptoms: Persistent cough, blood in sputum
(hemoptysis), chest pain.
o May lead to bronchial obstruction and infections.
 Paraneoplastic Syndrome:
o Secretion of PTH-related protein → Hypercalcemia.
 Treatment:
o Surgery, chemotherapy, and radiation therapy.

3 Large Cell Carcinoma

 Definition: A poorly differentiated carcinoma that lacks the features of

adenocarcinoma and squamous cell carcinoma.
 Location: Can occur in any part of the lung.
 Characteristics:
o Aggressive behavior.
o Tends to metastasize early.
 Histology:
o Large, pleomorphic cells with prominent nucleoli.
 o High mitotic rate.
 Clinical Features:
o Rapid progression.
o Often diagnosed in advanced stages.
 Treatment:
o Primarily chemotherapy and radiotherapy.
o Surgery may be considered if detected early.

2. SMALL CELL LUNG CANCER (SCLC)

What is SCLC?

Small Cell Lung Cancer accounts for 10–15% of lung cancers and is
characterized by very rapid growth, early metastasis, and neuroendocrine
differentiation. It is considered the most aggressive form of lung cancer. This
type is almost exclusively seen in heavy smokers.

Characteristics of SCLC:

 Origin: Arises from Kulchitsky cells, which are neuroendocrine cells of

the bronchial lining.
 Histology:
o Small round cells with scant cytoplasm.
o High nuclear-to-cytoplasmic ratio.
o “Salt and pepper” chromatin.
o Frequent mitoses and necrosis.
 Growth and Spread:
o Very rapid doubling time.
o Early lymphatic and hematogenous metastasis to brain, liver,
bone, and adrenal glands.
 Symptoms:
o Chronic cough, chest pain, weight loss, shortness of breath.
 o Neurological or endocrine symptoms due to paraneoplastic
syndromes.

Comparison Table: NSCLC vs. SCLC

Feature NSCLC SCLC

Prevalence 85–90% of lung cancers 10–15%

Adenocarcinoma,
Subtypes Single subtype
Squamous, Large cell
Growth rate Slower Rapid

Metastasis Later in course Early and widespread

Very strong (almost all
Smoking link Strong (esp. squamous)
cases)
Rarely useful due to
Surgery possible? Often yes
metastasis
Paraneoplastic
Rare Common
syndromes

Prognosis Relatively better Poor

Causes of Lung Cancer

Lung cancer develops due to a combination of environmental

exposures, lifestyle factors, occupational hazards, and genetic
predispositions that lead to DNA damage, uncontrolled cell proliferation, and
malignant transformation.

A. Tobacco Smoking – Primary Cause

 Responsible for ~85–90% of all lung cancer cases.

 Cigarette smoke contains >7,000 chemicals, of which at least 70 are
carcinogenic (e.g., polycyclic aromatic hydrocarbons, nitrosamines,
benzene, formaldehyde, arsenic).
  Mechanism:
o Carcinogens bind to DNA → mutations in tumor suppressor genes
(p53, RB) and oncogenes (KRAS, EGFR).
o Creates DNA adducts → defective repair → uncontrolled growth.
 Dose-dependent risk:
o Pack-years (packs/day × years smoked) correlate with incidence.
o Risk persists even after quitting but decreases progressively over
10–15 years.

B. Secondhand Smoke

 Non-smokers exposed to environmental tobacco smoke have 20–30%

higher lung cancer risk.
 Particularly harmful for children and long-term cohabiting adults.

C. Environmental and Occupational Carcinogens

1. Radon Gas:
o Radioactive gas released from soil and rocks; accumulates in
poorly ventilated homes.
o Second leading cause of lung cancer in non-smokers.
2. Asbestos Exposure:
o Strongly linked to mesothelioma and increases lung cancer risk
synergistically with smoking.
3. Silica, Nickel, Chromium, Arsenic:
o Occupational exposure in mining, welding, glass, and metal
industries.
4. Diesel Exhaust and Air Pollution:
o Long-term exposure to particulate matter (PM2.5) increases risk.
D. Radiation

 Previous thoracic radiation therapy for cancers (e.g., breast cancer,

lymphoma) can lead to lung malignancies years later.

E. Genetic Factors

 Family history increases susceptibility.

 Inherited polymorphisms affecting carcinogen metabolism (e.g., CYP1A1)
or DNA repair genes increase risk.
 Some subtypes (especially adenocarcinomas in non-smokers) are
associated with mutations:
o EGFR, ALK, ROS1, KRAS, BRAF.

F. Chronic Lung Diseases

 Chronic Obstructive Pulmonary Disease (COPD) and pulmonary

fibrosis increase cancer risk due to chronic inflammation and epithelial
injury.

SIGNS AND SYMPTOMS OF LUNG CANCER

Lung cancer often remains asymptomatic in its early stages and

symptoms typically appear when the disease is locally advanced or has
metastasized. The clinical presentation can be classified into:

 Local (pulmonary) symptoms

 Regional symptoms (due to local spread)
 Systemic symptoms (due to metastasis or paraneoplastic
syndromes)

1. Local (Intrathoracic) Symptoms:

These result from the primary tumor within the lung or bronchi.
a) Chronic Cough:

 Most common presenting symptom.

 Caused by irritation or obstruction of bronchial mucosa.
 Often dry at first, but may become productive.
 If a smoker presents with a new cough or a change in chronic cough,
lung cancer must be ruled out.

b) Hemoptysis (Coughing up Blood):

 Occurs due to tumor erosion of blood vessels.

 May range from blood-streaked sputum to massive bleeding.
 Particularly common in squamous cell carcinoma due to central location.

c) Dyspnea (Shortness of Breath):

 May result from airway obstruction, pleural effusion, atelectasis, or

tumor burden.
 Can be gradual or sudden in onset.

d) Wheezing:

 Caused by partial airway obstruction.

 Typically unilateral, unlike asthmatic wheezing.

e) Chest Pain:

 Pleuritic (sharp, localized) if the pleura is involved.

 Dull or persistent if the chest wall or ribs are infiltrated.

2. Regional (Locally Advanced) Symptoms:

These occur when the tumor extends into adjacent structures.

a) Hoarseness:
  Involvement of the recurrent laryngeal nerve (left more common).
 Suggestive of mediastinal invasion.

b) Dysphagia:

 Tumor compressing the esophagus.

 May indicate advanced disease.

c) Superior Vena Cava (SVC) Syndrome:

 Compression of the SVC by tumor or lymph nodes.

 Symptoms: facial puffiness, periorbital edema, dilated neck veins,
cyanosis.
 More common in small cell lung cancer.

d) Pancoast Syndrome:

 Tumor in the lung apex (superior sulcus tumor).

 Invasion of brachial plexus and sympathetic chain.
 Symptoms: shoulder/arm pain, muscle wasting of hand, Horner’s
syndrome (ptosis, miosis, anhidrosis).

e) Pleural Effusion:

 Tumor invasion into pleural space.

 Causes breathlessness, dullness on percussion, decreased breath
sounds.

3. Systemic Symptoms:

These reflect the overall cancer burden and presence of paraneoplastic

syndromes.

a) Weight Loss:
  Unintentional and progressive.
 Due to tumor metabolism and appetite suppression.

b) Fatigue:

 Disproportionate to activity.
 Result of anemia, cytokine release, or cancer cachexia.

c) Fever and Night Sweats:

 Occur due to cytokine release or infection secondary to tumor necrosis.

4. Paraneoplastic Syndromes:

Common in small cell lung cancer due to neuroendocrine activity.

Syndrome Pathophysiology Clinical Features

ADH secretion by tumor Hyponatremia,
SIADH
cells confusion, seizures
Weight gain, moon face,
Cushing's Syndrome ACTH secretion
HTN, hyperglycemia
Nausea, vomiting,
Hypercalcemia PTHrP secretion
confusion, arrhythmia
Autoantibodies to
Lambert-Eaton Proximal muscle
presynaptic calcium
Myasthenic Syndrome weakness
channels

DIAGNOSIS OF LUNG CANCER

1. Clinical Evaluation:
 Thorough history: smoking status, occupational exposures (e.g.,
asbestos), family history.
 Physical examination: respiratory findings (e.g., crackles, dullness),
lymphadenopathy, signs of metastasis.
2. Imaging:
a) Chest X-ray:
 First-line, but limited sensitivity.
 May show mass, collapse, consolidation, or effusion.
b) Chest CT Scan:
 Gold standard.
 Identifies tumor size, shape, lymphadenopathy, vascular invasion.
c) PET-CT:
 Detects metabolically active tissue (using FDG).
 Assesses local and distant metastasis.
d) MRI:
 Used especially for suspected brain metastasis.
3. Sputum Cytology:
 Examination of expectorated sputum for malignant cells.
 Best for central tumors.
4. Bronchoscopy:
 Endoscopic evaluation of tracheobronchial tree.
 Allows biopsy, brushing, and washing.
 Can perform Endobronchial Ultrasound (EBUS) for lymph node
sampling.
5. Biopsy Techniques:
 CT-guided percutaneous needle biopsy for peripheral lesions.
 Mediastinoscopy for sampling mediastinal nodes.
 Thoracoscopy for pleural involvement.
6. Histopathology:
 Differentiates between NSCLC and SCLC.
 IHC markers: TTF-1, Napsin-A (adenocarcinoma), p40 (squamous),
synaptophysin (SCLC).
7. Molecular Testing and Biomarkers:
 Especially important in NSCLC.
 Involves identification of biomarkers, which are specific genes, proteins,
or molecules that indicate the presence and behavior of a tumor.
 Examples of lung cancer biomarkers:
o EGFR (Epidermal Growth Factor Receptor) mutations
o ALK (Anaplastic Lymphoma Kinase) rearrangements
o ROS1, KRAS, BRAF mutations
o PD-L1 (Programmed Death-Ligand 1) expression level
 These biomarkers help in:
o Selecting targeted therapies or immunotherapies.
o Predicting treatment response.
o Monitoring disease progression or recurrence.

Screening of Lung Cancer

Screening aims to detect lung cancer at an early, treatable stage

before symptoms appear. Early detection significantly improves survival.

A. Who Should Be Screened? (High-Risk Groups)

According to USPSTF (U.S. Preventive Services Task Force) 2021:

 Age: 50–80 years.

  Smoking History: ≥20 pack-years.
 Status: Current smokers or those who quit within the last 15 years.
 Health: Fit for curative treatment if cancer is found.

B. Recommended Screening Method

Low-Dose Computed Tomography (LDCT):

 Uses ~90% less radiation than standard CT.

 Detects small nodules (<1 cm) missed by chest X-rays.
 Annual LDCT reduces lung cancer mortality by 20–25% (proven by
NLST trial).

C. Other Techniques

 Chest X-ray & Sputum Cytology:

o Historically used but not effective in reducing mortality.
 Biomarkers:
o Under research: circulating tumor DNA, microRNAs,
autoantibodies.

D. Benefits

 Detects early-stage cancers (Stage I-II) when surgical cure is possible.

 Reduces overall mortality in high-risk groups.

E. Limitations and Risks

 False positives: Lead to unnecessary biopsies or surgeries.

 Radiation exposure: Cumulative risk with annual scans.
 Overdiagnosis: Some detected nodules may never become clinically
significant.
Treatment of Lung Cancer

Treatment Goals:

 Curative: Early-stage disease.

 Palliative: Advanced/metastatic stage to relieve symptoms and prolong
life.

A. NSCLC TREATMENT

1. Early Stage (Stage I-IIA):

 Surgery: Lobectomy, pneumonectomy, segmentectomy.

 Adjuvant chemotherapy: Improves survival.
 SBRT: For medically inoperable cases.

2. Locally Advanced (Stage IIB-IIIA):

 Chemoradiotherapy: Platinum-based chemo + radiation.

 Surgery: Possible after downstaging.

3. Advanced/Metastatic (Stage IIIB-IV):

 Targeted therapy: EGFR inhibitors (Erlotinib), ALK inhibitors

(Crizotinib).
 Immunotherapy: PD-1/PD-L1 inhibitors (Pembrolizumab).
 Chemotherapy: Platinum-doublets (Cisplatin + Pemetrexed).

B. SCLC TREATMENT

1. Limited Stage:

 Chemoradiotherapy: Cisplatin + Etoposide with thoracic radiation.

 PCI (Prophylactic Cranial Irradiation): Prevents brain metastasis.
2. Extensive Stage:

 Chemotherapy: Cisplatin/Carboplatin + Etoposide.

 Immunotherapy: Atezolizumab or Durvalumab + chemo.
 Palliative care: For symptom relief and quality of life.

Prevention of Lung Cancer

Preventing lung cancer involves reducing exposure to carcinogens and

promoting protective health behaviors. Prevention can be categorized as
primary, secondary, and tertiary.

A. Primary Prevention (Avoiding Cancer Initiation)

1. Tobacco Control:
o Quit smoking: The single most effective preventive measure.
o Use behavioral counseling, nicotine replacement therapy, and
medications (varenicline, bupropion).
o Public policies: Taxation, smoke-free laws, graphic warnings,
banning advertising.
2. Avoid Secondhand Smoke:
o Implement home and workplace smoke-free policies.
3. Reduce Environmental/Occupational Exposure:
o Test homes for radon gas; use proper ventilation and mitigation
systems.
o Use protective gear in workplaces handling asbestos, silica, or
chemicals.
o Comply with occupational safety regulations.
4. Improve Air Quality:
o Reduce exposure to outdoor air pollution and indoor biomass
smoke (e.g., from cooking).
5. Healthy Diet and Lifestyle:
 o Diets rich in fruits, vegetables, antioxidants may provide some
protection.
o Regular physical activity enhances lung function and immunity.

B. Secondary Prevention (Early Detection)

 Implement LDCT screening for high-risk populations.

 Regular medical check-ups for people with strong occupational exposure
or genetic predisposition.

C. Tertiary Prevention (Preventing Recurrence/Progression)

 In lung cancer survivors:

o Strict smoking cessation (reduces risk of second primary lung
cancers).
o Regular surveillance imaging.
o Pulmonary rehabilitation to optimize lung health.

Mouth/Oral Cancer:

Mouth cancer, also called oral cancer or oral cavity carcinoma, is a

type of head and neck cancer that originates in the tissues of the oral cavity. It
most commonly arises in the squamous epithelial lining of the mouth, hence
the term oral squamous cell carcinoma (OSCC), which accounts for more
than 90% of all mouth cancers.

Common Sites of Mouth Cancer:

 Tongue (lateral borders)
 Floor of the mouth
 Buccal mucosa (inner cheek)
 Gingiva (gums)
 Hard palate
 Alveolar ridge
  Retromolar trigone
 Lips (especially lower lip in sun-exposed individuals)

Anatomy of Mouth / Oral Cavity:

The oral cavity is the anterior portion of the digestive tract and includes
multiple anatomical structures lined primarily by stratified squamous
epithelium. The oral cavity constitutes the entrance to the alimentary canal
and plays a key role in digestion, speech, taste, and immune defense. It is
divided anatomically into:

Vestibule:

 Space between the lips/cheeks and the teeth/gums.

Oral Cavity Proper:

 Enclosed by the teeth, hard and soft palates, floor of the mouth, and
anterior two-thirds of the tongue.

Lined by:

 Stratified squamous epithelium (non-keratinized in most regions;

keratinized in hard palate, gingiva, and dorsal tongue).

Key anatomical components:

 Tongue: Involved in taste, speech, and swallowing; contains intrinsic

and extrinsic muscles.
 Hard Palate: Bony anterior roof of the mouth.
 Soft Palate: Muscular posterior roof of the mouth; closes off
nasopharynx during swallowing.
 Floor of Mouth: Under the tongue; contains ducts of submandibular
and sublingual glands.
  Gingiva: Surrounds the base of the teeth.
 Retromolar Trigone: Posterior area behind the last molars.

Lymphatic Drainage:

 Rich lymphatic network draining to submental, submandibular, and

deep cervical lymph nodes—facilitates early metastasis.

How Mouth / Oral Cancer Develops:

Oral cancer development is a multi-step process involving

accumulation of genetic mutations and epigenetic alterations due to long-
term carcinogen exposure (e.g., tobacco, alcohol, HPV).

➤ Pathogenesis Steps:

1. Initiation:
o Carcinogens like tobacco introduce DNA mutations in oral
epithelial cells.
o Mutations commonly affect tumor suppressor genes (e.g., p53)
and proto-oncogenes.
2. Promotion:
o Continued exposure to irritants and inflammation promotes clonal
expansion of mutated cells.
o Results in epithelial dysplasia.
3. Progression:
o Dysplastic lesions evolve into carcinoma in situ (non-invasive).
o Once basement membrane is breached → becomes invasive
carcinoma.
4. Metastasis:
o Invasion of blood and lymphatic vessels leads to spread to cervical
lymph nodes and distant organs (lungs, bones, liver).
Types of Mouth / Oral Cancer:

Mouth cancer is classified based on the type of tissue from which it

originates (histological) and its anatomical location within the oral cavity.

A. Histological Classification:

This classification is based on the type of cells from which the cancer
arises, as confirmed through histopathology.

1. Squamous Cell Carcinoma (SCC):

 The most prevalent type, accounting for over 90% of oral cancers.

 Originates in the squamous epithelial lining of the oral mucosa.

 Can be:

o Keratinizing: produces keratin; tends to be slower growing.

o Non-keratinizing: more aggressive.

 Often associated with tobacco and alcohol use.

 Subtyped by degree of differentiation:

o Well-differentiated: close to normal squamous cells, grows slower.

o Moderately differentiated: intermediate behavior.

o Poorly differentiated: highly atypical cells, aggressive.

2. Verrucous Carcinoma:

 A low-grade, slow-growing variant of SCC.

 Warty or cauliflower-like appearance.

 Rarely metastasizes but can be locally invasive.

 Common in elderly, tobacco-chewing individuals.

3. Minor Salivary Gland Tumors:

 Originate in minor salivary glands located in the palate, buccal mucosa,

or lips.

 Types:

o Mucoepidermoid carcinoma: mixture of mucus-secreting and

epidermoid cells.

o Adenoid cystic carcinoma: slow-growing, perineural invasion is

common.

4. Malignant Melanoma:

 Rare in the oral cavity.

 Arises from melanocytes, often pigmented.

 Common sites: hard palate, maxillary gingiva.

 Poor prognosis due to late detection and early metastasis.

5. Lymphomas:

 Include non-Hodgkin’s lymphomas involving lymphoid tissues of the

palate or tonsils.

 Typically seen in immunocompromised individuals.

B. Anatomical Classification:

Defines mouth cancer based on the location of the primary lesion within
the oral cavity.

1. Tongue (Lateral Borders):

 Most common site for oral cancer.

  Associated with sharp teeth, tobacco use.

 High risk of early lymphatic spread.

2. Buccal Mucosa:

 More common in South and Southeast Asia due to betel nut chewing and
smokeless tobacco.

 Tumors can easily spread to cheek and adjacent areas.

3. Floor of the Mouth:

 High-risk site due to thin mucosa and rich vascular supply.

 Cancer here often invades the mandible and sublingual space.

4. Gingiva and Alveolar Ridge:

 Tumors often mimic dental infections or trauma.

 May present with tooth mobility or gingival swelling.

5. Hard and Soft Palate:

 Less common but can involve salivary gland tumors.

 May present as ulcers or masses that interfere with speech or

swallowing.

6. Retromolar Trigone:

 Area behind last molars.

 Difficult to inspect, often diagnosed late.

 Associated with restricted mouth opening and trismus.

7. Lip (mostly Lower Lip):

 Caused primarily by sun exposure, pipe smoking.

  Usually well-differentiated and slow-growing.

 Early diagnosis leads to good prognosis.

Causes of Oral Cancer

Oral cancer (most commonly oral squamous cell carcinoma) develops

due to chronic exposure to carcinogens, infections, and genetic alterations
that cause epithelial cell mutations, uncontrolled growth, and malignant
transformation. Its causes are multifactorial and often synergistic.

A. Tobacco Use (Smoked and Smokeless)

 Cigarette, bidi, cigar, and pipe smoking are the leading causes.
 Smokeless forms (chewing tobacco, gutkha, khaini, betel quid with
tobacco) directly expose the oral mucosa to carcinogens.
 Tobacco smoke contains polycyclic aromatic hydrocarbons,
nitrosamines, benzene, arsenic, all of which:
o Form DNA adducts.
o Cause mutations in tumor suppressor genes (p53, p16).
o Lead to dysplasia and eventually invasive cancer.
 Risk increases with:
o Quantity and duration of use.
o Combination of smoking and alcohol.

B. Alcohol Consumption

 Alcohol itself is not a strong carcinogen but acts as a co-carcinogen:

o Increases mucosal permeability to tobacco carcinogens.
o Metabolizes to acetaldehyde, a direct DNA-damaging compound.
 Combined tobacco + alcohol use → 30–40× higher risk.
C. Betel Quid, Areca Nut, and Lime

 Common in South and Southeast Asia.

 Arecoline (from areca nut) causes:
o Fibroblast stimulation → Oral Submucous Fibrosis (OSMF) →
high cancer risk.
o DNA damage and collagen cross-linking.
 Lime (calcium hydroxide) enhances carcinogen absorption.

D. Chronic Mechanical Irritation

 Ill-fitting dentures, sharp teeth, or habitual cheek biting can cause

repeated trauma, leading to non-healing ulcers that may become
malignant.

E. Viral Infections

 Human Papillomavirus (HPV), especially type 16, is linked to

oropharyngeal cancers:
o Viral proteins E6 and E7 inactivate p53 and Rb.
o Leads to genetic instability and malignant transformation.
 HPV-positive cancers often occur in younger individuals and may have a
better prognosis.

F. Poor Oral Hygiene and Chronic Infections

 Chronic irritation, poor dentition, and periodontal disease increase

susceptibility.
 Infections may enhance inflammation-driven carcinogenesis.
G. Nutritional Deficiencies

 Low intake of vitamins A, C, E, and iron:

o Reduces antioxidant defense.
o Iron deficiency (Plummer–Vinson syndrome) → mucosal atrophy
and cancer risk.

H. Genetic Predisposition

 Family history of head and neck cancers.

 Inherited conditions:
o Fanconi anemia.
o Dyskeratosis congenita.

I. Environmental and Occupational Exposures

 Wood dust, polycyclic aromatic hydrocarbons, pesticides.

 Long-term UV radiation exposure → lip cancers.

Signs & Symptoms of Mouth / Oral Cancer:

Mouth cancer can present with a wide range of symptoms. These may
initially be subtle and painless, which leads to delayed diagnosis in many
cases.

A. Early Signs:

 Persistent ulcers or sores: A non-healing ulcer lasting more than two

weeks is a red flag.
 Color changes in the oral mucosa:
o Leukoplakia – white patches.
o Erythroplakia – red, velvety lesions.
o Speckled leukoplakia – mixed red and white, higher malignant
potential.
  Painless lump or thickening in cheek, tongue, or floor of mouth.

B. Progressive Symptoms:

 Pain or burning sensation in the mouth or throat.

 Difficulty chewing, swallowing (dysphagia), or speaking (dysarthria).
 Numbness or paraesthesia (e.g., tingling of tongue or lip).
 Tooth mobility or dentures not fitting as before.
 Bleeding from lesion sites.
 Trismus – inability to open mouth fully.
 Halitosis – persistent foul smell.

C. Advanced Signs:

 Weight loss due to eating difficulty.

 Referred ear pain (via glossopharyngeal nerve).
 Swelling in jaw or cervical lymphadenopathy indicating metastasis.
 Change in voice if tumor affects oropharynx.

Diagnosis of Mouth / Oral Cancer:

Diagnosis of oral cancer is a multistep process that combines clinical

examination, histopathology, imaging, and sometimes molecular testing.

A. Clinical Evaluation:

 Inspection and palpation of oral cavity, tongue, floor of mouth, palate,

and neck nodes.
 Evaluation of ulcer margins, consistency, fixity, and induration.

B. Adjunctive Screening Tools:

 Toluidine blue staining: Helps detect dysplasia by staining DNA-rich

malignant cells.
  Brush cytology: Collects exfoliated cells for cytologic analysis.
 Autofluorescence devices: Detect abnormal mucosal tissue.

C. Biopsy – Gold Standard:

 Incisional biopsy: For large or infiltrative lesions.

 Excisional biopsy: For small, well-demarcated lesions.
 Specimens undergo histopathological grading and typing.

D. Imaging Studies:

 CT scan (contrast-enhanced): Evaluates bony invasion

(mandible/maxilla).
 MRI: Best for soft tissue spread and nerve involvement.
 Ultrasound with FNAC: Cervical lymph node assessment.
 PET-CT scan: Whole-body staging, detects distant metastasis.

E. Additional Investigations:

 Blood tests: Hemoglobin (anemia), nutritional status.

 HPV typing: In cases of oropharyngeal tumors.
 IHC (Immunohistochemistry): p16, p53, Ki-67 for molecular
characterization.

Screening of Oral Cancer

Early detection is critical because oral cancer is often curable at early

stages but has a poor prognosis when diagnosed late.

A. Target Population for Screening

 Individuals with:
o Chronic tobacco/alcohol use.
o Betel quid/areca nut chewing.
 o Oral potentially malignant disorders (leukoplakia, erythroplakia,
OSMF).
o Family history of oral cancers.
o Age >40 years with lifestyle risk factors.

B. Screening Methods

1. Visual Inspection and Palpation

 Most practical and cost-effective method.

 Performed by trained health workers or dentists.
 Steps:
o Inspect lips, buccal mucosa, tongue (lateral borders), floor of
mouth, palate.
o Palpate for nodules or induration.
 Can detect leukoplakia, erythroplakia, non-healing ulcers.

2. Toluidine Blue Staining

 Stains areas of high DNA content (dysplastic/malignant cells) deep blue.

 Helps identify suspicious lesions for biopsy.

3. Autofluorescence and Chemiluminescence Devices

 Special light devices detect loss of tissue fluorescence → indicates

dysplastic changes.
 Adjunct to clinical screening, especially in high-risk clinics.

4. Brush Biopsy / Cytology

 Collects superficial cells for cytological analysis.

 Useful for suspicious but small lesions.

5. Biopsy (Gold Standard for Diagnosis)

  Any lesion persisting >2 weeks should undergo incisional biopsy.
 Histopathology confirms diagnosis.

6. Imaging

 For staging rather than initial screening:

o MRI, CT, PET-CT.

C. Organized Screening Programs

 In high-risk countries (e.g., India), community-based oral visual

screening programs have reduced oral cancer mortality.
 WHO recommends training primary healthcare workers for mass
screening.

D. Limitations of Screening

 Requires trained personnel.

 Risk of false positives (benign lesions mistaken as malignant).
 Patient compliance for follow-up biopsies is critical.

Treatment of Mouth / Oral Cancer:

Treatment is personalized based on tumor stage, location, histology,

and general condition of the patient. It is best managed by a
multidisciplinary team (MDT).

A. Surgical Management:

 Wide local excision with clear margins (>1 cm).

 Neck dissection:
o Selective: Only involved lymph node levels.
o Modified radical: Preserves some structures.
 o Radical: Removes sternocleidomastoid, IJV, spinal accessory
nerve.
 Mandibulectomy/Maxillectomy/Glossectomy as required.
 Reconstructive surgery:
o Free flaps: Radial forearm, fibula, or anterolateral thigh flap.
o Local pedicled flaps for smaller defects.

B. Radiation Therapy:

 Definitive RT for early-stage, inoperable tumors.

 Adjuvant RT for post-surgical cases with risk factors (positive margins,
nodal spread).
 Techniques:
o Intensity-Modulated Radiation Therapy (IMRT).
o Brachytherapy for localized, smaller lesions.

C. Chemotherapy:

 Induction chemotherapy: For bulky, advanced tumors before

surgery/RT.
 Concurrent chemoradiotherapy (CCRT): Improves local control.
 Drugs used: Cisplatin, 5-FU, Docetaxel, Carboplatin.

D. Targeted Therapy and Immunotherapy:

 Cetuximab (anti-EGFR) for patients unsuitable for platinum-based

chemo.
 Nivolumab / Pembrolizumab (PD-1 inhibitors): Approved for
recurrent/metastatic SCC.

E. Supportive and Palliative Care:

 Nutritional support: Oral supplements, feeding tubes.

  Pain management: NSAIDs, opioids.
 Physiotherapy: For speech and swallowing rehabilitation.
 Palliative RT: For bleeding, pain, or airway obstruction.
 Psychosocial support: Essential for quality of life.

Prevention of Oral Cancer

Prevention aims to reduce risk factors, detect premalignant lesions

early, and prevent recurrence. It is categorized as primary, secondary, and
tertiary prevention.

A. Primary Prevention (Avoiding Cancer Initiation)

1. Tobacco and Alcohol Control:

o Quit smoking and chewing tobacco.
o Avoid combined tobacco + alcohol use.
o Implement public health measures (taxation, bans, awareness
campaigns).
2. Avoid Areca Nut, Betel Quid, and Lime:
o Stop chewing gutkha, pan masala.
o Educate communities on OSMF risk.
3. Improve Diet:
o High intake of fresh fruits, vegetables, antioxidants.
o Correct vitamin and iron deficiencies.
4. Oral Hygiene:
o Regular brushing, dental care, and treatment of chronic irritations.
o Ensure well-fitting dentures.
5. HPV Vaccination:
o May prevent HPV-related oropharyngeal cancers.
6. Reduce Occupational Risks:
o Use protective masks in industries with dust/chemical exposure.
7. Sun Protection:
 o Use lip balms with SPF to prevent lip cancers.

B. Secondary Prevention (Early Detection and Treatment)

 Conduct regular oral self-examination (mirror inspection).

 Community screening for high-risk groups.
 Prompt biopsy and treatment of:
o Leukoplakia
o Erythroplakia
o Oral Submucous Fibrosis
 Laser therapy, cryotherapy, or surgical excision of premalignant lesions.

C. Tertiary Prevention (Preventing Recurrence/Progression)

 Post-treatment surveillance: Regular follow-up every 3–6 months.

 Lifestyle modifications:
o Permanent cessation of risk habits.
o Nutritional support to rebuild immune strength.
 Rehabilitation:
o Speech therapy.
o Dental prosthetics for functional restoration.

Skin Cancer

Skin cancer is a malignant transformation of skin cells, characterized

by unregulated cell proliferation, local invasion, and potential to
metastasize. It arises when genetic and epigenetic alterations, often
induced by ultraviolet (UV) radiation, cause DNA damage in the cells of the
epidermis. Skin cancer is the most common type of cancer globally,
particularly among fair-skinned populations and those with high sun exposure.

Anatomy of the Skin

 Understanding skin structure is essential to grasp how different cancers
arise from different cellular origins. The human skin is a multifunctional organ
that forms the interface between the body and the external environment. It
plays vital roles in protection, sensation, immune surveillance,
thermoregulation, and vitamin D synthesis. The skin consists of three main
layers:

1. Epidermis

 The outermost layer of the skin.

 Made of stratified squamous keratinized epithelium.
 Avascular—nourished via diffusion from the dermis.
 Constantly renews every 28–40 days through keratinocyte turnover.

Layers (from bottom to top):

1. Stratum basale (germinativum)

o Single layer of mitotically active basal keratinocytes.
o Also contains melanocytes (produce melanin), Merkel cells
(mechanoreceptors), and basal stem cells.
o Responsible for regeneration of the epidermis.
2. Stratum spinosum
o 5–10 layers of keratinocytes connected by desmosomes
(intercellular junctions giving a spiny appearance).
o Contains Langerhans cells (antigen-presenting immune cells).
3. Stratum granulosum
o 1–5 layers of keratinocytes accumulating keratohyalin granules
and lamellar bodies, which contribute to the epidermal barrier.
4. Stratum lucidum (only in thick skin)
o Thin translucent layer of anucleate keratinocytes found only in
palms and soles.
5. Stratum corneum
 o 15–20 layers of dead, flattened corneocytes embedded in lipid
matrix.
o Provides the primary barrier to water loss and microbial
invasion.

2. Dermis

 Middle layer; composed of collagen, elastin, and extracellular matrix.

 Contains blood vessels, lymphatics, nerve endings, hair follicles, and
sweat/sebaceous glands.
 Lies beneath the epidermis.
 Composed of connective tissue derived from the mesoderm.
 Provides mechanical strength, elasticity, and vascular support to the
epidermis.

Layers:

1. Papillary Dermis
o Loose connective tissue.
o Contains capillaries, sensory nerve endings, Meissner’s
corpuscles, and dermal papillae that interlock with the epidermis.
2. Reticular Dermis
o Dense irregular connective tissue with type I collagen and elastic
fibers.
o Contains hair follicles, sebaceous glands, sweat glands, blood
vessels, lymphatics, fibroblasts, mast cells, and macrophages.

Nerve and Sensory Structures:

 Free nerve endings (pain, temperature)

 Pacinian corpuscles (vibration and pressure)
 Ruffini endings (skin stretch)
 Meissner corpuscles (fine touch)
3. Hypodermis (Subcutaneous tissue)

 Deepest skin layer.

 Composed primarily of adipose tissue and loose connective tissue.
 Serves as a cushion, energy reservoir, and insulator.
 Anchors the skin to underlying fascia, muscles, and bones.
 Contains larger blood vessels, lymphatics, and nerves supplying the
dermis.

How Skin Cancer Develops

Skin cancer arises through a multistep carcinogenic process involving

genetic mutations, epigenetic alterations, and environmental exposures,
particularly to ultraviolet (UV) radiation. The process by which normal skin
cells transform into malignant cells is known as multistage tumorigenesis,
comprising initiation, promotion, and progression phases. Each of these
phases reflects a biological shift towards greater malignancy and invasive
potential.

A. Initiation

 In this early stage, carcinogenic insult, especially UVB (290–320 nm)

and UVA (320–400 nm) radiation, causes direct DNA damage in
epidermal cells.
 UVB causes cyclobutane pyrimidine dimers (CPDs) and 6-4
photoproducts, which result in DNA distortion.
 If DNA repair mechanisms (e.g., nucleotide excision repair) fail, these
mutations become permanent.
 Mutations commonly affect tumor suppressor genes (like TP53) and
proto-oncogenes (e.g., RAS, BRAF).
 In basal cell carcinoma (BCC), mutations in the PTCH1 gene (part of the
hedgehog signaling pathway) are frequent.
B. Promotion

 At this stage, clonal expansion of mutated cells occurs.

 These initiated cells proliferate abnormally, especially under continued
environmental stress (UV exposure, inflammation).
 Promotion is considered reversible, and involves epigenetic alterations
that regulate gene expression without changing DNA sequence.
 Chronic exposure to UV radiation can suppress local immunity by
reducing Langerhans cells and releasing immunosuppressive
cytokines, promoting survival of dysplastic cells.

C. Progression

 At this phase, cells acquire additional mutations that allow for

autonomous growth, angiogenesis, invasion, and immune evasion.
 Transition from actinic keratosis → SCC in situ → invasive SCC
exemplifies this sequence.
 Melanocytes can transform into melanoma cells by acquiring mutations
in BRAF, NRAS, and inactivation of CDKN2A (which encodes p16 and
p14).
 Tumors gain the ability to degrade the basement membrane using
enzymes like matrix metalloproteinases (MMPs), allowing invasion
into the dermis and metastasis via lymphatics and blood vessels.

D. Molecular and Cellular Hallmarks

 Evading apoptosis (via p53 inactivation)

 Sustained proliferative signaling (e.g., MAPK pathway activation in
melanoma)
 Limitless replicative potential (telomerase activation)
 Inducing angiogenesis (via VEGF upregulation)
 Tissue invasion and metastasis
E. Immunoediting and Escape

 The immune system initially recognizes and eliminates aberrant skin

cells.
 In later stages, tumors adapt through immune editing: escaping
immune surveillance by downregulating MHC I, upregulating immune
checkpoint ligands (e.g., PD-L1), and creating an immunosuppressive
microenvironment.

Skin carcinogenesis is therefore a complex interplay of genetic susceptibility,

environmental triggers (primarily UV radiation), immune dysfunction, and
chronic tissue stress, which together drive normal cells toward malignancy.

Types of Skin Cancer

Skin cancer is a malignant condition characterized by the uncontrolled

proliferation of cells within the skin. It is broadly categorized based on the type
of cell involved, with each type displaying distinct histopathological
characteristics, clinical features, and prognostic behavior. The three major
types of skin cancer include:

1. Basal Cell Carcinoma (BCC) – arising from the basal layer of the
epidermis.
2. Squamous Cell Carcinoma (SCC) – originating from squamous
keratinocytes of the epidermis.
3. Melanoma – developing from melanocytes responsible for skin
pigmentation.

Each type exhibits a unique pattern of growth, invasion, and potential for
metastasis.

A. Basal Cell Carcinoma (BCC)

Definition: Basal Cell Carcinoma is the most common and least aggressive
form of skin cancer. It originates from basal keratinocytes in the stratum
basale of the epidermis and accounts for approximately 70–80% of all non-
melanoma skin cancers.

Etiology and Pathogenesis:

 Strongly associated with intermittent and intense UV exposure,

particularly UVB.
 Genetic mutations, particularly in the PTCH1 gene (a tumor suppressor
gene of the Hedgehog signaling pathway), play a critical role in tumor
development.
 Risk factors include fair skin, history of sunburns, ionizing radiation
exposure, immunosuppression, and arsenic exposure.

Clinical Presentation:
  Appears as a pearly, translucent papule or nodule with rolled borders
and surface telangiectasia.
 Central ulceration may occur, leading to the term “rodent ulcer.”
 Lesions are most commonly located on sun-exposed areas, such as the
face, nose, ears, and neck.

Histological Subtypes:

 Nodular: Lobules of basaloid cells with peripheral palisading.

 Superficial: Tumor nests confined to the epidermis.
 Morpheaform/Sclerosing: Thin strands infiltrating fibrotic dermis.
 Pigmented: Contains melanin and mimics melanoma.

Behavior and Prognosis:

 Rarely metastasizes.
 Can cause significant local tissue destruction if untreated.
 Excellent prognosis with early diagnosis and surgical excision or Mohs
micrographic surgery.

B. Squamous Cell Carcinoma (SCC)

Definition: SCC arises from keratinocytes of the epidermis and is the second
most common skin cancer. It has a higher propensity for metastasis than
BCC.

Etiology and Pathogenesis:

 Cumulative and chronic UV exposure is the primary risk factor.

 Other contributing factors include:
o Actinic keratosis (precursor lesion)
o Bowen’s disease (SCC in situ)
o HPV infection, particularly types 16 and 18
 o Chronic wounds, scars, burns (Marjolin ulcers)
o Chemical carcinogens (e.g., arsenic)
o Immunosuppression (e.g., post-transplant, HIV)

Clinical Features:

 Presents as a scaly, erythematous, firm plaque or ulcerated nodule.

 Commonly found on sun-exposed regions, such as the face, scalp, ears,
hands, and lower lips.
 Lesions may be painful and bleed.

Histopathology:

 Atypical squamous cells with eosinophilic cytoplasm.

 Formation of keratin pearls and intercellular bridges.
 Degree of differentiation correlates with prognosis.

Behavior and Prognosis:

 Has a moderate metastatic potential, particularly to regional lymph

nodes.
 Prognosis depends on depth of invasion, location, and host immune
status.
  Treatment typically involves surgical excision, electrodessication and
curettage, or radiation therapy.

C. Melanoma

Definition: Melanoma is a highly aggressive malignancy arising from

melanocytes, the pigment-producing cells in the basal layer of the epidermis.
Despite being less common, it is responsible for the majority of skin cancer-
related deaths.

Etiology and Pathogenesis:

 Intermittent intense sun exposure and blistering sunburns are major

risk factors.
 Genetic predispositions include:
o Mutations in BRAF, NRAS, and CDKN2A (p16).
o Presence of dysplastic nevi and familial melanoma syndromes.

ABCDE Criteria for Clinical Detection:

 Asymmetry
 Border irregularity
 Color variation
 Diameter >6 mm
 Evolution (change in size, shape, color, or symptoms)

Clinical Subtypes:

1. Superficial Spreading Melanoma:

o Most common subtype.
o Begins with radial (horizontal) growth phase.
o Appears as a flat, irregular, multicolored lesion.
2. Nodular Melanoma:
 o Exhibits early vertical growth.
o Rapidly enlarging, dome-shaped lesion.
o Poorer prognosis due to early dermal invasion.
3. Lentigo Maligna Melanoma:
o Occurs in elderly individuals with chronic sun damage.
o Slow-growing flat lesion on sun-exposed skin.
4. Acral Lentiginous Melanoma:
o Found on palms, soles, and nail beds.
o More common in individuals with darker skin.
o Often diagnosed at a later stage.

Histopathology:

 Atypical melanocytes with pagetoid spread through epidermis.

 Depth of invasion is measured by Breslow thickness.
 Ulceration, mitotic activity, and lymphovascular invasion are
important prognostic markers.

Behavior and Prognosis:

 High potential for local invasion, lymphatic, and hematogenous

spread (e.g., lungs, liver, brain).
 Prognosis depends on stage at diagnosis and molecular features.
 Requires wide surgical excision; advanced cases need immunotherapy
(e.g., checkpoint inhibitors), targeted therapy, or chemotherapy.

Causes of Skin Cancer

Skin cancer results from uncontrolled proliferation of abnormal skin

cells triggered by genetic mutations primarily caused by environmental
factors. The three main types—Basal Cell Carcinoma (BCC), Squamous Cell
Carcinoma (SCC), and Melanoma—share some causes but also have distinct
risk factors.
A. Ultraviolet (UV) Radiation – Primary Cause

 Solar UV exposure (especially UVB 290–320 nm) is the leading cause.

 UV light induces DNA damage:
o Formation of thymine dimers.
o Mutations in tumor suppressor genes (e.g., p53) and oncogenes.
 Cumulative exposure → BCC & SCC.
 Intermittent, intense exposure → Melanoma.
 Artificial UV sources (tanning beds) also significantly increase
melanoma risk.

B. Fair Skin Phenotype

 Individuals with:
o Light skin, blue/green eyes, blond/red hair.
o Low melanin → reduced natural UV protection.
 Higher risk of sunburns and DNA damage.

C. History of Sunburns

 Severe blistering sunburns, particularly during childhood, increase

lifetime melanoma risk.

D. Genetic Predisposition

 Family history of melanoma.

 Syndromes:
o Xeroderma pigmentosum: Defective DNA repair → extreme UV
sensitivity.
o Familial atypical multiple mole melanoma (FAMMM)
syndrome: CDKN2A mutations.
E. Immunosuppression

 Organ transplant recipients (long-term immunosuppressants).

 HIV/AIDS patients.
 Reduced immune surveillance → higher SCC and BCC incidence.

F. Pre-existing Skin Lesions

 Actinic keratosis → SCC.

 Congenital giant nevi → melanoma.
 Chronic scars, ulcers, and burn wounds → Marjolin’s ulcers (SCC).

G. Chemical and Environmental Carcinogens

 Arsenic exposure (contaminated water, occupational hazards) → multiple

BCCs/SCCs.
 Polycyclic aromatic hydrocarbons.
 Ionizing radiation (prior radiotherapy).

H. Other Factors

 Chronic mechanical trauma.

 Male gender (higher outdoor exposure).
 Older age (cumulative DNA damage).

Signs & Symptoms of Skin Cancer

The clinical presentation of skin cancer can vary widely depending on the
type of malignancy, its anatomical location, stage of progression, and the
patient’s skin type. However, identifying these signs early can be crucial to
improving prognosis and treatment outcomes. Below are the detailed and
specific signs and symptoms associated with the three major types of skin
cancer: Basal Cell Carcinoma (BCC), Squamous Cell Carcinoma (SCC), and
Melanoma. Skin cancer often presents with visual and tactile changes in the
skin. These manifestations vary depending on the type of cancer, its growth
behavior, and its location on the body. Understanding the nuanced signs and
symptoms is vital for early detection, accurate clinical suspicion, and timely
diagnosis.

1. Basal Cell Carcinoma (BCC)

BCC is the most common and least aggressive type of skin cancer. It is
derived from the basal keratinocytes of the epidermis and rarely metastasizes,
but it can cause extensive local tissue destruction if left untreated.

Characteristic Signs & Symptoms:

 Pearly or translucent papule: Typically pink, flesh-colored, or slightly

pigmented, with a shiny surface.
 Rolled border: A classic finding where the edge of the lesion is raised
and rounded.
 Central ulceration: Often seen as a depression in the center of the
lesion – known as a “rodent ulcer.”
 Telangiectasia: Tiny visible blood vessels on the lesion surface.
 Non-healing sore: A lesion that may bleed, crust over, partially heal, and
recur repeatedly.
 Slow, persistent growth: Lesion enlarges gradually over months or
years.

Common Locations:

 Sun-exposed areas such as nose, cheeks, eyelids, ears, neck, and

shoulders.

Warning Signs:

 A new bump or nodule that does not go away.

  A sore that bleeds with minimal trauma and does not heal.

2. Squamous Cell Carcinoma (SCC)

Overview:
SCC arises from epidermal keratinocytes, often due to cumulative UV
damage. It is more aggressive than BCC, with a higher potential for local
invasion and regional lymph node metastasis.

Characteristic Signs & Symptoms:

 Firm, rough, scaly plaque or nodular lesion: May appear red or pink,
with a hardened or thickened surface.
 Ulceration and crusting: The surface may break down, leading to
bleeding, scabbing, or oozing.
 Pain or tenderness: Lesion may be symptomatic, especially if invasive.
 Warty growth or cutaneous horn: In some variants, hyperkeratosis may
cause a horn-like projection.
 Rapid growth: More noticeable change over weeks to months compared
to BCC.

Common Locations:

 Face, scalp, ears, lower lip, backs of hands, and forearms.

High-Risk Features:

 Lesions on mucosal areas or chronic scars.

 Occurrence in immunocompromised individuals.
 Recurrent or previously irradiated skin areas.

3. Melanoma
Overview:
Melanoma is a malignant tumor of melanocytes, the pigment-producing cells.
It is the most dangerous form of skin cancer due to its aggressive nature and
high potential for metastasis.

Key Diagnostic Tool – The ABCDE Criteria:

 A – Asymmetry: One half of the lesion is unlike the other.

 B – Border irregularity: Edges are ragged, notched, or poorly defined.
 C – Color variation: Multiple colors such as tan, brown, black, blue, red,
or white.
 D – Diameter: Greater than 6 mm (size of a pencil eraser), although
some melanomas may be smaller.
 E – Evolving: Any change in size, shape, color, or new symptoms such
as bleeding or itching.

Additional Symptoms:

 New mole in adulthood or a changing mole in shape or color.

 Ulceration, itching, burning, or pain in an existing mole.
 Bleeding or oozing from pigmented areas.
 Dark streaks under the nails (subungual melanoma).
 Acral lentiginous melanoma: Often seen as a flat, dark lesion on the
palms, soles, or under the nails—commonly in darker-skinned
individuals.

Common Locations:

 Men: Back, chest, head, neck.

 Women: Legs and back.
 Also found in mucosal areas (mouth, eyes, genitalia).

Progression Warning:
  Melanoma may spread vertically into the dermis and reach lymphatic
and blood vessels.
 Early detection is key to survival.

General Red Flag Symptoms for All Skin Cancers:

 A non-healing lesion lasting more than 3–4 weeks.

 A new lesion in previously clear skin.
 A sore or growth that recurs after minor trauma.
 Pigmented changes with itching, burning, or bleeding.
 Skin changes in scars, burn sites, or areas of chronic inflammation.

Diagnosis of Skin Cancer

The diagnosis of skin cancer is a multifaceted and stepwise approach

involving clinical evaluation, specialized dermoscopic tools, tissue sampling,
histological assessment, and in some cases, molecular and imaging techniques.
Accurate diagnosis is essential not only for confirming malignancy but also for
determining the histological subtype, invasiveness, and metastatic
potential, all of which guide prognosis and therapeutic decisions.

1. Clinical Evaluation

Objective:

To detect and evaluate potentially malignant lesions through thorough

patient interaction and physical examination.

A. History Taking:

 Onset & duration of the lesion.

 Changes over time: color, shape, border, bleeding, itching, pain.
 Personal or family history of skin cancer, especially melanoma.
 Past history of excessive sun exposure or indoor tanning.
  Occupation (e.g., outdoor work increases risk).
 Use of photosensitizing medications.
 Immunosuppression (e.g., post-transplant, HIV/AIDS).
 History of radiation exposure, burns, or chronic ulcers.

B. Visual Examination:

 Inspection under adequate lighting, with or without magnification.

 Note the lesion's symmetry, borders, color, diameter, and evolution
(ABCDE).
 Full skin survey, including scalp, nails, mucous membranes, and
genital areas.
 Palpation of regional lymph nodes if invasive malignancy is suspected.

Key Clinical Indicators:

 Lesion that does not heal within 3–4 weeks.

 A new mole or change in an existing mole in an adult.
 Persistent itching, bleeding, or painful skin growth.
 Any pigmented streak under a fingernail (subungual melanoma).
 Wart-like lesion or scaly plaque that grows rapidly (suggestive of SCC).

2. Dermoscopy (Dermatoscopy)

Definition:

A non-invasive diagnostic tool that allows enhanced visualization of

epidermal and superficial dermal structures not visible to the naked eye,
using polarized light and magnification.

Use in Diagnosis:

 Improves the specificity and sensitivity of clinical assessment.

  Helps differentiate benign nevi from malignant melanoma and
keratinocyte cancers (BCC, SCC).

Dermoscopic Patterns:

 Melanoma:
o Asymmetric pigmentation
o Blue-white veil
o Atypical pigment network
o Irregular streaks and dots
 Basal Cell Carcinoma:
o Arborizing (tree-like) telangiectasia
o Ovoid nests of pigmentation
o Shiny white areas and ulceration
 Squamous Cell Carcinoma:
o White circles
o Central keratin mass
o Dotted or irregular vessels

Advantages:

 Non-invasive
 Can reduce unnecessary biopsies
 Enables digital monitoring of suspicious lesions over time

3. Skin Biopsy – The Definitive Diagnostic Step

Biopsy is considered the gold standard for diagnosing skin cancer, providing
definitive histological confirmation.

Types of Biopsy Techniques:

1. Excisional Biopsy:
 o Removes the entire lesion with a narrow margin of normal skin.
o Preferred method for suspected melanoma to assess full lesion
depth (Breslow thickness).
o Also ideal for small BCC/SCC.
2. Incisional Biopsy:
o Removes only a portion of the lesion.
o Used when the lesion is too large for complete excision or located
in a cosmetically sensitive area.
3. Punch Biopsy:
o Uses a cylindrical tool to extract a full-thickness core.
o Ideal for raised lesions or nodules.
4. Shave Biopsy:
o Surface removal using a blade.
o Often used for superficial BCC or SCC but not recommended for
suspected melanoma due to inadequate depth assessment.

Important Considerations:

 Include dermal tissue to assess invasion.

 In melanoma, accurate measurement of Breslow depth is critical for
staging.
 Incorrect biopsy type can lead to underdiagnosis or inaccurate staging.

4. Histopathological Examination (Microscopic Evaluation of Tissue)

Histopathological examination remains the gold standard for

confirming the diagnosis of skin cancer. After a skin biopsy is taken, the
tissue undergoes fixation, processing, embedding, sectioning, and staining
(commonly with Hematoxylin and Eosin – H&E) before being examined by a
dermatopathologist under a microscope.

Key Objectives:
  To confirm malignancy
 To identify the tumor subtype
 To determine tumor differentiation, depth of invasion, and other
prognostic features

A. Basal Cell Carcinoma (BCC) – Microscopic Features:

 Basaloid cells with large nuclei and scant cytoplasm.

 Peripheral palisading: alignment of nuclei along the periphery of tumor
nests.
 Clefting artifact between tumor islands and surrounding stroma (due to
mucin).
 Low mitotic activity.
 Histologic subtypes include nodular, superficial, morpheaform
(infiltrative), pigmented, and micronodular – each with differing
aggressiveness.

B. Squamous Cell Carcinoma (SCC) – Microscopic Features:

 Atypical squamous cells infiltrating the dermis.

 Keratin pearl formation: concentric rings of keratinized cells, typically
seen in well-differentiated tumors.
 Intercellular bridges connecting adjacent tumor cells.
 Degree of differentiation (well, moderately, or poorly differentiated) is
crucial in assessing aggressiveness.
 Evidence of perineural invasion or lymphovascular invasion suggests
higher metastatic potential.

C. Melanoma – Microscopic Features:

 Proliferation of atypical melanocytes in nests or single units at the

dermo-epidermal junction.
  Pagetoid spread: upward migration of melanocytes into upper layers of
the epidermis.
 Breslow Thickness: Measured in millimeters from the top of the
granular layer to the deepest point of tumor invasion; strongest predictor
of prognosis.
 Clark Level: Anatomical level of invasion (I–V) but now less commonly
used.
 Other features: ulceration, mitotic rate, regression, tumor-infiltrating
lymphocytes, satellite lesions, and margins.

5. Staging Investigations for Advanced Cases

For skin cancers, especially invasive SCC and melanoma, staging

investigations are necessary to determine tumor extent, nodal involvement,
and distant metastasis. This information is vital for TNM classification
(Tumor, Node, Metastasis) and treatment planning.

When to Initiate Staging:

 Melanoma >1 mm Breslow depth

 Presence of ulceration, high mitotic index, or positive margins
 Palpable lymph nodes or systemic symptoms
 Recurrent or high-risk SCC (e.g., poorly differentiated, perineural
invasion)

A. Imaging Modalities:

1. Ultrasound (USG) of Lymph Nodes:

o First-line for assessing regional nodal metastasis.
o Identifies size, shape, and internal structure of nodes.
2. CT (Computed Tomography):
o Evaluates deep tissue invasion, bone erosion, and visceral
spread.
 o Often used in head and neck SCC and advanced melanoma.
3. MRI (Magnetic Resonance Imaging):
o Offers better contrast for soft tissue and nerve involvement.
o Preferred for periorbital, scalp, or CNS involvement.
4. PET-CT (Positron Emission Tomography - CT):
o Functional imaging that detects metabolic activity of cancer cells.
o Valuable in identifying occult metastasis, especially in
melanoma.

B. Sentinel Lymph Node Biopsy (SLNB):

 Used to assess early nodal metastasis, especially in melanoma with

Breslow thickness >1 mm or other high-risk features.
 Involves radioactive tracer and/or blue dye injection near the primary
tumor.
 The first draining lymph node (“sentinel node”) is surgically removed and
analyzed.
 Positive SLNB often leads to completion lymph node dissection or
systemic therapy.

6. Molecular and Immunohistochemical (IHC) Testing

These advanced diagnostic tools help:

 Confirm the tumor lineage in ambiguous histological cases.

 Classify tumors into subtypes.
 Identify actionable mutations for targeted therapies or prognostic
stratification.

Immunohistochemical Markers

These are antibodies used in pathology to detect specific proteins

expressed by tumor cells.
1. S-100 Protein

 Type: Immunohistochemical marker

 Expression: Found in melanocytes, Schwann cells, Langerhans cells,
and other neural crest-derived cells.
 Usage:
o Highly sensitive for melanoma (almost all melanomas are S-100
positive).
o Not very specific as it stains many other cell types.
 Significance: A good screening marker for melanoma but must be
confirmed with more specific markers.

2. HMB-45 (Human Melanoma Black-45)

 Type: Monoclonal antibody that detects a premelanosome protein.

 Expression: Specific to melanocytic cells.
 Usage:
o Positive in melanoma, especially active and immature
melanocytes.
o Typically negative in benign nevi.
 Significance: More specific than S-100 but less sensitive.

3. Melan-A (MART-1 – Melanoma Antigen Recognized by T-cells 1)

 Type: Melanocyte differentiation antigen

 Expression: Found in normal melanocytes and melanomas.
 Usage:
o Used to confirm melanocytic lineage.
o Often used in conjunction with S-100 and HMB-45.
 Significance: Highly specific and commonly used to diagnose melanoma.

4. SOX10
  Type: Nuclear transcription factor
 Expression: Expressed in melanocytes and peripheral nerve sheath
tumors.
 Usage:
o Sensitive marker for melanoma.
o Also expressed in Schwannomas, neurofibromas, and salivary
gland tumors.
 Significance: High sensitivity and nuclear staining pattern aids in
accurate diagnosis.

5. Ber-EP4 (Berkeley Epithelial Antigen)

 Type: Epithelial cell adhesion molecule (EpCAM)

 Expression: Present in basal epithelial cells and BCC, absent in SCC.
 Usage:
o Positive in basal cell carcinoma.
o Negative in squamous cell carcinoma.
 Significance: Helps distinguish BCC from SCC in difficult cases.

6. EMA (Epithelial Membrane Antigen)

 Type: Glycoprotein expressed on epithelial and some mesothelial cells.

 Expression: Positive in SCC, adenocarcinomas, and other epithelial
tumors.
 Usage:
o Negative in BCC, positive in SCC.
 Significance: Used to differentiate SCC (EMA+) from BCC (EMA−).

7. p63

 Type: Nuclear transcription factor (p53 homolog)

 Expression: Found in squamous epithelium, basal cells of epidermis.
 Usage:
 o Strongly positive in squamous cell carcinoma.
o Also expressed in urothelial carcinoma and myoepithelial cells.
 Significance: Marker for squamous differentiation.

Molecular Markers (Genetic Mutations)

These markers help identify gene alterations involved in cancer

development and provide targets for therapy.

8. BRAF (v-raf murine sarcoma viral oncogene homolog B1)

 Function: Serine/threonine kinase in the MAPK pathway.

 Mutation: V600E mutation seen in ~50% of melanomas.
 Significance:
o Targetable mutation: Responds to BRAF inhibitors (e.g.,
vemurafenib, dabrafenib).
o Used in personalized treatment planning for advanced melanoma.

9. NRAS (Neuroblastoma RAS Viral Oncogene Homolog)

 Function: GTPase in the MAPK signaling pathway.

 Mutation: Found in ~15–25% of melanomas.
 Significance:
o Associated with more aggressive melanoma.
o Not directly targetable, but may influence selection of MEK
inhibitors.

10. KIT (CD117, stem cell factor receptor)

 Function: Receptor tyrosine kinase important in melanocyte

development.
 Mutation: Seen in acral lentiginous, mucosal, and chronically sun-
damaged melanomas.
  Significance:
o Targeted therapy with imatinib may be beneficial if mutated.

11. TERT Promoter (Telomerase Reverse Transcriptase)

 Function: Increases telomerase activity, allowing indefinite cell

replication.
 Mutation: Frequently seen in melanoma, BCC, and SCC.
 Significance:
o Associated with aggressive behavior and poor prognosis.
o Potential future target for therapy and prognostication.

12. TP53 (Tumor Protein 53)

 Function: Tumor suppressor gene controlling DNA repair, apoptosis.

 Mutation: Common in UV-induced squamous cell carcinoma.
 Significance:
o Marker of genetic instability.
o Associated with high-grade and therapy-resistant tumors.

13. PTCH1 (Patched 1 Gene)

 Function: Negative regulator of the Hedgehog signaling pathway.

 Mutation: Found in sporadic basal cell carcinomas and in Gorlin
syndrome.
 Significance:
o Aberrant Hedgehog pathway activation → uncontrolled basal cell
proliferation.
o Targeted by Hedgehog inhibitors like vismodegib.

Screening of Skin Cancer

 Screening aims to detect skin cancers at an early, treatable stage.
Unlike some cancers, skin cancer screening can be visual and non-invasive.

A. Who Should Be Screened? (High-Risk Groups)

1. People with:
o Fair skin, multiple moles (>50), or atypical nevi.
o History of skin cancer or precancerous lesions.
o Immunosuppression.
o Frequent intense sun exposure or tanning bed use.
2. Family history of melanoma.
3. Organ transplant recipients.

B. Screening Methods

1. Total Body Skin Examination (TBSE)

 Performed by dermatologists.
 Inspects entire skin (scalp, nails, mucosa).
 Detects new or changing lesions.

2. Dermoscopy (Epiluminescence Microscopy)

 Handheld device magnifies skin structures and pigment networks.

 Improves diagnostic accuracy for melanoma, BCC, and SCC.
 Algorithms:
o ABCDE Rule:
 A: Asymmetry
 B: Border irregularity
 C: Color variation
 D: Diameter >6 mm
 E: Evolving lesion (size, shape, symptoms)
o 7-point checklist for subtle melanomas.
3. Digital Imaging and Total Body Photography

 Monitors high-risk patients over time.

 Detects new lesions or changes in existing moles.

4. Patient Self-Examination

 Monthly self-check using mirrors.

 Focus on ABCDE criteria.

5. Biopsy (Diagnostic Confirmation)

 Any suspicious lesion must be biopsied:

o Excisional biopsy (preferred for melanoma).
o Punch/shave biopsy for BCC/SCC.
 Histopathology confirms type, depth, and margins.

6. Imaging

 Only for advanced cases:

o Sentinel lymph node biopsy.
o PET/CT scans for melanoma staging.

C. Screening Guidelines

 USPSTF: Insufficient evidence for routine population-wide screening but

recommends clinician vigilance.
 AAD/NCCN: Encourage annual professional skin checks for high-risk
individuals.
 WHO: Emphasizes education, sun protection, and self-examination.

Treatment of Skin Cancer

The treatment of skin cancer depends on several key factors, including:

  Type of skin cancer (e.g., BCC, SCC, melanoma)
 Stage and depth of invasion
 Anatomic location
 Histological subtype
 Patient-specific factors (age, comorbidities, cosmetic concerns, immune
status)

The main goals of treatment are complete tumor eradication,

prevention of recurrence, cosmetic preservation, and minimizing
morbidity.

1. Treatment of Basal Cell Carcinoma (BCC)

BCC is usually slow-growing and rarely metastasizes, so treatment

focuses on local control.

A. Surgical Excision

 Gold standard for BCC.

 Excision with 3–5 mm margins depending on tumor risk.
 Indicated for both nodular and superficial BCCs.
 Histological margin control is critical.

B. Mohs Micrographic Surgery

 Tissue-sparing, staged excision with real-time histological analysis.

 Highest cure rate (>99%) for primary BCC.
 Best for:
o Lesions on face, eyes, nose, lips
o Recurrent BCC
o Ill-defined or morpheaform variants
C. Electrodessication and Curettage (ED&C)

 Destruction by scraping and cauterization.

 Used for superficial, low-risk nodular BCCs.
 Not ideal for facial areas due to poor cosmetic outcomes.

D. Topical Therapies

 Imiquimod cream (immune modulator) and 5-Fluorouracil (5-FU):

o Approved for superficial BCC only.
o Typically used for small lesions on the trunk or extremities.

E. Radiation Therapy

 Reserved for:
o Elderly or non-surgical candidates
o Recurrent or inoperable tumors
 Used as primary treatment or post-operatively if margins are positive.

F. Targeted Therapy (for advanced BCC)

 Vismodegib, Sonidegib – Hedgehog pathway inhibitors

 Used in:
o Locally advanced unresectable BCC
o Metastatic BCC
 Side effects: muscle cramps, alopecia, dysgeusia

2. Treatment of Squamous Cell Carcinoma (SCC)

SCC has a higher risk of local invasion and metastasis, so treatment

must be more aggressive and cautious.
A. Surgical Excision

 First-line for most SCCs.

 Excision with 4–6 mm margin for low-risk SCC and up to 10 mm for
high-risk tumors.

B. Mohs Micrographic Surgery

 Ideal for:
o High-risk tumors
o Tumors on head, neck, hands
o Recurrent or deeply infiltrative SCC
 Allows maximum tissue conservation and complete margin
assessment.

C. Electrodessication and Curettage (ED&C)

 Suitable for small, superficial, well-differentiated SCC in non-critical

areas.

D. Radiation Therapy

 Used for:
o Poor surgical candidates
o Adjuvant treatment after incomplete excision
o Perineural invasion or regional spread
 Fractionated external beam therapy is commonly used.

E. Systemic Chemotherapy or Immunotherapy (Advanced SCC)

 For metastatic or unresectable SCC

 Cemiplimab (PD-1 inhibitor) is FDA-approved.
 Other agents: carboplatin + 5-FU (rarely used now).
3. Treatment of Melanoma

Melanoma is the most aggressive skin cancer due to its high metastatic
potential. Early-stage melanoma can be cured surgically, but advanced cases
require systemic therapies.

A. Surgical Excision

 Primary treatment for all localized melanomas.

 Margins depend on Breslow thickness:
o <1 mm: 1 cm margin
o 1–2 mm: 1–2 cm
o 2 mm: 2 cm
 Excision of the primary lesion plus sentinel lymph node biopsy (SLNB) if
>1 mm thickness or other high-risk features.

B. Sentinel Lymph Node Biopsy (SLNB)

 Used to detect occult regional metastasis.

 If positive → complete lymph node dissection or adjuvant systemic
therapy.

C. Adjuvant and Systemic Therapy (for Stage III & IV)

1. Immunotherapy:
o Checkpoint inhibitors:
 Anti-PD-1: Nivolumab, Pembrolizumab
 Anti-CTLA-4: Ipilimumab
o These therapies enhance the immune response against
melanoma cells.
2. Targeted Therapy (for BRAF-mutated melanoma):
o BRAF inhibitors: Vemurafenib, Dabrafenib
o MEK inhibitors: Trametinib, Cobimetinib
 o Used in combination for better outcomes.
3. Chemotherapy (less preferred):
o Dacarbazine, Temozolomide – limited effectiveness.
4. Oncolytic Viral Therapy:
o Talimogene laherparepvec (T-VEC): Modified herpes virus
injected into lesions to boost immune response.

D. Radiation Therapy

 Not a primary treatment.

 Used in:
o Palliative care for brain/bone metastases
o Adjuvant setting in nodal disease

Other Modalities (for All Skin Cancers)

A. Photodynamic Therapy (PDT)

 Used for superficial BCC, actinic keratosis, and in-situ SCC.

 Combines topical photosensitizing agent (e.g., aminolevulinic acid) with
light activation.
 Benefits: good cosmetic outcome, minimal scarring.

B. Cryotherapy

 Used for precancerous lesions and very superficial cancers.

 Liquid nitrogen destroys tissue by rapid freezing.

C. Laser Therapy

 Rarely used; reserved for superficial skin changes or cosmetic

indications.

Prevention of Skin Cancer

 Prevention strategies target reducing UV-induced DNA damage and
early removal of precancerous lesions. Prevention is divided into primary,
secondary, and tertiary levels.

A. Primary Prevention (Avoid Disease Initiation)

1. Sun Protection
o Avoid sun exposure between 10 a.m.–4 p.m.
o Wear protective clothing, wide-brimmed hats, and sunglasses.
o Use broad-spectrum sunscreen (SPF ≥30) daily, reapply every 2
hours.
o Avoid tanning beds.
2. Public Health Campaigns
o Programs like “Slip! Slop! Slap!” (Australia) successfully reduced
melanoma incidence.
o Education about early childhood sun safety (most lifetime UV
exposure occurs before age 20).
3. Avoid Environmental Carcinogens
o Reduce arsenic exposure.
o Minimize unnecessary ionizing radiation.
4. Immunocompromised Care
o Close dermatological monitoring.
o Adjust immunosuppressive regimens when possible.

B. Secondary Prevention (Early Detection and Intervention)

 Regular self-skin exams.

 Professional TBSE for high-risk individuals.
 Early treatment of actinic keratoses (precursors to SCC):
o Cryotherapy, topical 5-FU, imiquimod.
C. Tertiary Prevention (Prevent Recurrence/Progression)

 In patients previously treated for skin cancer:

o Lifelong follow-up.
o Prompt excision of new suspicious lesions.
o Continuous sun protection.
o Education on self-monitoring.

Cervical Cancer

Cervical cancer originates on the surface of the cervix and develops when
normal cervical cells undergo changes and become precancerous. Nearly all
cases are caused by infection with human papillomavirus (HPV), a virus
transmitted primarily through sexual contact. The risk of developing cervical
cancer can be significantly reduced through regular screening tests, such as
the Pap smear, and by receiving the HPV vaccine.

Fig: Cervix (courtesy:[Link])

 Global burden: 4th most common cancer in women worldwide.

 Etiology: Strongly associated with persistent infection by high-risk
human papillomavirus (HPV) strains, primarily HPV-16 and HPV-18.
 Cervical cancer is a malignant neoplasm that arises from the epithelial
lining of the cervix—the lower part of the uterus that opens into the vagina. It
is one of the most preventable cancers in women, largely due to the
effectiveness of early detection through screening and the availability of
vaccines against human papillomavirus (HPV), the principal cause. The
majority of cervical cancers develop in the transformation zone, the area
where the squamous epithelium of the ectocervix meets the columnar
epithelium of the endocervix. Because it often progresses slowly, cervical
cancer offers multiple opportunities for early intervention and cure.

Anatomy of the Cervix

The cervix is the lower part of the uterus that connects the uterine
cavity to the vagina. It acts as a passageway for menstrual blood, sperm, and
childbirth, and plays a crucial role in fertility and protection against infections.

Fig: Anatomy of Cervix (courtesy:[Link])

 This diagram highlights the microscopic (histological) anatomy of the
cervix, dividing it into functional and cellular regions:

1. Endocervix

 Location: The inner part of the cervical canal, closest to the uterus.
 Lined by: Columnar epithelial cells.
 Function:
o These tall, mucus-secreting cells produce cervical mucus that
changes in consistency throughout the menstrual cycle to either
facilitate or block sperm.
o They also help trap and eliminate pathogens.
 These cells are more delicate and susceptible to HPV infection when
exposed.

2. Squamocolumnar Junction (SCJ)

 This is the transition zone where the columnar epithelium of the

endocervix meets the squamous epithelium of the ectocervix.
 This junction is dynamic and changes location with age, pregnancy,
and hormonal influences.
 Clinically important because it is the site where most cervical
precancers and cancers begin.

3. Transformation Zone

 The area between the original SCJ and the new SCJ (due to metaplasia).
 Contains sub-columnar reserve cells that can undergo metaplasia—a
normal physiological process where:
o Columnar cells are replaced by immature squamous epithelial
cells.
o These immature cells later mature into squamous epithelium.
  This zone is particularly vulnerable to HPV infection and is the
primary site of origin for cervical intraepithelial neoplasia (CIN) and
cervical cancer.

4. Ectocervix

 Location: The outer part of the cervix that protrudes into the vagina.
 Lined by: Mature stratified squamous epithelial cells.
 These cells are tougher and adapted to the acidic vaginal environment.
 Most squamous cell carcinomas originate here or within the
transformation zone.

How Cervical Cancer Develops

Cervical cancer arises through a stepwise transformation of normal

cervical epithelial cells into malignant cells, usually triggered by persistent
infection with high-risk human papillomavirus (HPV). This development is a
multistep process involving viral integration, genetic mutations, and
progressive cellular changes that disrupt normal cell growth, differentiation,
and apoptosis.

1. Initial Infection with HPV

The human papillomavirus (HPV) is the central cause of cervical cancer.

It is a double-stranded DNA virus transmitted through sexual contact.
Infection typically occurs at the transformation zone of the cervix—the
junction between the squamous epithelium of the ectocervix and the columnar
epithelium of the endocervix.

Not all HPV infections cause cancer. In fact, most are cleared by the
immune system within 1–2 years. However, persistent infection with high-
risk HPV types (especially HPV-16 and HPV-18) can lead to cancer.
2. Viral Integration and Oncoprotein Expression

In high-risk HPV infections, the virus may integrate its DNA into the
host genome, especially when the infection persists over months or years.
Once integrated, the virus expresses oncogenic proteins:

 E6: Inhibits p53, a tumor suppressor gene involved in DNA repair and
apoptosis. Without functional p53, cells with damaged DNA continue to
divide.
 E7: Inactivates retinoblastoma protein (Rb), a key regulator of the cell
cycle. This promotes unregulated progression from the G1 to the S
phase, allowing for uncontrolled cellular proliferation.

The combined action of E6 and E7 leads to genomic instability,

inhibition of programmed cell death, and evasion of growth control signals—
hallmarks of cancer.

3. Cervical Intraepithelial Neoplasia (CIN) – Precancerous Stage

As the infected cells accumulate genetic damage, they begin to exhibit

dysplasia—abnormal changes in size, shape, and organization. This is known
as Cervical Intraepithelial Neoplasia (CIN), which represents the
precancerous phase.

CIN Involvement of
Description
Grade Epithelium

CIN I Lower 1/3 Mild dysplasia (LSIL)

CIN II Lower 2/3 Moderate dysplasia

Severe dysplasia or Carcinoma in situ

CIN III Full thickness
(HSIL)

 Low-grade lesions (CIN I) often regress spontaneously.

  High-grade lesions (CIN II & III) carry a significant risk of progressing
to invasive cancer if left untreated.

4. Progression to Invasive Cancer

If CIN III or carcinoma in situ is not detected and treated, abnormal

cells may penetrate the basement membrane and invade the underlying
cervical stroma, marking the transition to invasive cervical cancer.

Key features of invasion:

 Loss of cell polarity and differentiation

 Neoangiogenesis (formation of new blood vessels to supply the tumor)
 Local tissue destruction
 Potential to invade nearby structures (e.g., vagina, parametrium,
bladder, rectum)
 Eventual spread to lymph nodes and distant organs (metastasis)

This process usually takes 10 to 15 years, offering a large window of

opportunity for screening and early treatment.

5. Factors Influencing Progression

While HPV is the initiating factor, the following increase the likelihood of
progression from infection to cancer:

 Persistent infection with high-risk HPV strains

 Co-infection with other sexually transmitted infections (e.g., HIV,
Chlamydia)
 Immunosuppression (e.g., HIV/AIDS, organ transplant recipients)
  Smoking (local immune suppression and mutagenic effects)
 Long-term oral contraceptive use
 High parity and early childbirth
 Lack of screening or follow-up

Types of Cervical Cancer

Cervical cancer primarily arises from the epithelial cells lining the
transformation zone of the cervix. It is classified primarily based on
histological cell types.

A. Squamous Cell Carcinoma (SCC)

 Accounts for ~70–80% of cervical cancers. The most common form.

 Originates from the squamous epithelial cells of the ectocervix.
 Closely associated with HPV-16 infection.
 Typically progresses from CIN lesions (Cervical Intraepithelial Neoplasia)
to invasive cancer.

B. Adenocarcinoma

 Represents 10–15% of cases.

 Arises from the glandular (columnar) cells of the endocervix.
 Commonly linked with HPV-18.
 More challenging to detect on Pap smears due to its endocervical
location.

C. Adenosquamous Carcinoma

 Comprises both squamous and glandular cell features.

 Less common but more aggressive.
D. Rare Types

 Neuroendocrine carcinoma
 Small cell carcinoma
 Glassy cell carcinoma
 These are aggressive and often diagnosed at an advanced stage.

Causes of Cervical Cancer

Primary Cause:

 Persistent infection with high-risk Human Papillomavirus (hrHPV)

types, particularly:
o HPV-16 (causes ~50% of cases)
o HPV-18 (~20% of cases)
o Other oncogenic types: 31, 33, 45, 52, and 58
 HPV is a sexually transmitted virus that integrates its genetic material
into host cervical epithelial cells.

 The viral oncogenes E6 and E7 play a central role in oncogenesis by

inactivating tumor suppressor proteins p53 and Rb, respectively.

 This disruption leads to genomic instability, dysregulated cell

proliferation, and eventual malignant transformation. Although HPV
infection is common, only persistent infection with high-risk types leads
to cervical cancer, typically over several years.

Signs and Symptoms

Cervical cancer is often asymptomatic in its early stages, making

screening critical. Symptoms typically arise in moderate to advanced
disease.

Common Symptoms:
  Post-coital bleeding (bleeding after sexual intercourse)
 Intermenstrual bleeding
 Menorrhagia or irregular periods
 Foul-smelling vaginal discharge
 Pelvic or lower abdominal pain
 Pain during intercourse (dyspareunia)

Advanced Disease Symptoms:

 Leg swelling (due to lymphatic obstruction)

 Hydronephrosis → flank pain (ureteral compression)
 Hematuria or rectal bleeding (invasion into bladder or rectum)
 Cachexia, anemia, or fatigue (systemic effects)

Diagnosis

What is Diagnosis?

Diagnosis is the process of confirming the presence, nature, and

extent of disease. It is conducted in:

 Individuals with abnormal screening test results

 Individuals who present with clinical signs and symptoms

Diagnosis involves more specific, definitive, and sometimes invasive

tests and leads to a confirmed medical condition that guides treatment.

Objectives of Cervical Cancer Diagnosis:

 Confirm the presence of cancer or pre-cancerous lesions

 Identify the histological type and grade
 Determine tumor size, extent of local invasion, lymph node
involvement, and metastasis (staging)
 Guide treatment planning
Diagnostic Methods for Cervical Cancer:

A. Colposcopy

 A magnified visual examination of the cervix using a colposcope.

 After applying acetic acid and/or Lugol’s iodine, abnormal areas turn
white or fail to stain.
 Suspicious areas are targeted for biopsy.
 Used after an abnormal Pap smear or positive HPV test.

B. Cervical Biopsy

 Tissue samples are taken from abnormal areas seen during colposcopy.
 Types:
o Punch biopsy – small sample from surface
o Endocervical curettage (ECC) – cells scraped from the
endocervical canal
o Cone biopsy – larger, cone-shaped sample including the
transformation zone, done via LEEP or cold knife conization
 Histopathological analysis determines:
o Whether CIN or invasive carcinoma is present
o Degree of differentiation
o Depth of invasion
o Margins

C. Imaging Studies (for Staging)

Used to assess tumor size, parametrial involvement, nodal spread, or

distant metastasis:

 MRI – most accurate for local tumor assessment

 CT scan – detects lymphadenopathy and visceral metastasis
 PET-CT – combines metabolic and anatomical imaging for staging
  Ultrasound – helpful for pelvic mass evaluation in some settings
 Cystoscopy and Proctoscopy – to evaluate bladder or rectal invasion in
advanced cases

Histopathological Diagnosis Includes:

 Tumor type: Squamous cell carcinoma, adenocarcinoma,

adenosquamous, etc.
 Tumor grade: Well, moderately, or poorly differentiated
 Presence of lymphovascular invasion
 Depth of stromal infiltration
 Margins: Clear, involved, or close
 Associated findings: CIN, HPV effect

Screening

What is Screening?

Screening is a proactive, population-based strategy used to detect

disease in asymptomatic individuals. The primary goal is early detection of
precancerous changes or early-stage cancer, when treatment is more
effective and survival rates are higher.

Screening is not meant to confirm disease, but to identify individuals

who may need further diagnostic evaluation.

Objectives of Cervical Cancer Screening:

 Detect Cervical Intraepithelial Neoplasia (CIN) before it progresses to

invasive cancer.
 Identify asymptomatic early-stage cervical cancer.
 Reduce incidence and mortality through timely intervention.
Screening Methods for Cervical Cancer:

A. Pap Smear (Papanicolaou Test)

 A cytological test that detects abnormal epithelial cells from the cervix.
 Cells are collected from the transformation zone using a brush or
spatula, spread on a slide (conventional) or in a liquid medium (liquid-
based cytology), and stained.
 Detects cellular changes associated with:
o CIN I–III (dysplasia)
o Carcinoma in situ
o Invasive cancer

B. HPV DNA Testing

 Detects high-risk HPV strains, particularly types 16 and 18.

 Can be done alone or in combination with Pap smear (co-testing).
 Highly sensitive for predicting future risk of cervical dysplasia and
cancer.
 Often used every 5 years when negative.

C. Visual Inspection with Acetic Acid (VIA)

 Low-cost, visual technique used in low-resource settings.

 Application of 3–5% acetic acid causes acetowhite areas in dysplastic
epithelium.
 Simple, immediate results, but less specific than Pap/HPV tests.

Who Should Be Screened and When?

Age Group Recommended Test & Frequency

21–29 years Pap smear every 3 years
30–65 years Pap + HPV co-testing every 5 years or Pap alone
 every 3 years
May discontinue screening if previous tests are
>65 years
normal

Treatment of Cervical Cancer

The treatment of cervical cancer depends on multiple clinical factors

including the FIGO stage, tumor size, histological subtype, lymph node
status, age, performance status, and the desire to preserve fertility. A
multidisciplinary approach involving gynecologic oncologists, radiation
oncologists, and medical oncologists is essential for optimal outcomes.

1. Treatment Based on Stage

Cervical cancer is treated differently depending on whether it is early-

stage, locally advanced, or metastatic. The FIGO 2018 staging system
(International Federation of Gynecology and Obstetrics) guides the
management plan.

A. Early-Stage Disease (Stage IA1 to IB1 and IIA1)

These stages refer to tumors that are confined to the cervix or upper
vagina, with no parametrial invasion and tumor size less than 4 cm.

1. Surgical Treatment:

Surgery is the primary modality of treatment in early-stage cervical

cancer.

 Conization (Cold Knife or LEEP):

o Indicated for Stage IA1 without lymphovascular invasion (LVI).
o Removes the transformation zone and part of the endocervical
canal.
 o Fertility-preserving option.
 Simple Hysterectomy:
o Suitable for Stage IA1 with LVI or very low-risk IA2.
o Removal of uterus and cervix without surrounding tissue.
 Radical Hysterectomy (Type II or III):
o Indicated for Stage IA2, IB1, and IIA1.
o Involves removal of uterus, cervix, upper one-third of vagina, and
parametrium.
o Often combined with pelvic lymphadenectomy to assess nodal
status.
 Radical Trachelectomy + Lymphadenectomy:
o Fertility-sparing surgery for Stage IA2 or small IB1 tumors (<2
cm).
o Removes cervix and upper vagina but preserves the uterus.

2. Adjuvant Therapy:

 Based on pathological risk factors from the surgical specimen:

o Intermediate-risk: Deep stromal invasion, LVI, large tumor size.
 May require adjuvant radiotherapy.
o High-risk: Positive lymph nodes, positive margins, or parametrial
invasion.
 Requires adjuvant concurrent chemoradiotherapy (CCRT).

B. Locally Advanced Disease (Stage IB2 to IVA)

This includes tumors larger than 4 cm, those with parametrial

involvement, or lower third of vaginal invasion. These cases are not
amenable to surgery due to the risk of incomplete resection.

Primary Treatment: Concurrent Chemoradiation

 External Beam Radiotherapy (EBRT):

 o Targets the pelvis, covering the primary tumor, uterus,
parametrium, and pelvic lymph nodes.
o Typically delivered over 5–6 weeks (45–50 Gy in 25–28 fractions).
 Intracavitary Brachytherapy:
o Delivers a high dose of radiation directly to the cervix and adjacent
tissues.
o Given after EBRT using radioactive isotopes (e.g., Iridium-192).
o Essential for improving local control and survival.
 Concurrent Chemotherapy:
o Weekly cisplatin (40 mg/m² IV) during EBRT.
o Acts as a radiosensitizer.
o Improves 5-year survival by ~10–15%.

C. Advanced and Metastatic Disease (Stage IVB)

This stage includes distant metastases to organs like lungs, liver, bone,
or extrapelvic lymph nodes. The goal of treatment is palliation, prolonging
survival, and symptom relief.

1. Systemic Chemotherapy:

 First-line regimen: Cisplatin + Paclitaxel ± Bevacizumab.

o Bevacizumab (anti-VEGF monoclonal antibody) improves survival.
 Carboplatin may be substituted in cisplatin-intolerant patients.

2. Targeted Therapy:

 Bevacizumab:
o Anti-angiogenic agent.
o Added to chemotherapy in eligible patients with advanced disease.
3. Immunotherapy:

 Pembrolizumab:
o PD-1 immune checkpoint inhibitor.
o Approved for PD-L1-positive recurrent or metastatic cervical
cancer.
o Enhances the body's immune response against tumor cells.

4. Radiotherapy for Palliation:

 Used to relieve symptoms such as:

o Pain, bleeding, ureteral obstruction, or neurological deficits.
 Also used for isolated recurrence in the pelvis or para-aortic nodes.

2. Special Considerations

A. Fertility Preservation

 Women desiring fertility can undergo radical trachelectomy with pelvic

lymph node dissection if tumor size is <2 cm and there's no lymph node
involvement.

B. Pregnancy

 Treatment depends on gestational age and stage of cancer.

 In early pregnancy and early-stage cancer, surgery may be delayed until
fetal viability.
 Advanced disease typically requires treatment regardless of gestation.

C. Elderly or Medically Unfit Patients

 May not tolerate radical surgery or chemoradiation.

 Individualized treatment plans may involve hypofractionated RT,
single-agent chemotherapy, or supportive care.
3. Follow-Up After Treatment

Patients require long-term surveillance to detect:

 Recurrence
 Late treatment-related complications

Typical follow-up includes:

 Pelvic examination every 3–6 months for the first 2 years, then annually.
 Pap smears or HPV testing depending on prior treatment.
 Imaging (CT/MRI) if recurrence is suspected.

4. Outcomes and Prognosis

Prognosis depends heavily on:

 FIGO stage at diagnosis

 Tumor size
 Lymph node status
 Histological grade
 Response to treatment

Prevention of Cervical Cancer

Cervical cancer is one of the most preventable malignancies, with a long

pre-invasive phase, identifiable causative agent (HPV), and effective preventive
interventions. Prevention strategies target each stage of disease development—
from avoiding initial infection to detecting precancerous lesions, and
treating early cancer to prevent recurrence.

Cervical cancer prevention is categorized into:

 Primary Prevention – Prevents disease onset

  Secondary Prevention – Detects and treats disease in the preclinical
phase
 Tertiary Prevention – Treats established disease and prevents
complications or recurrence

1. PRIMARY PREVENTION

What is Primary Prevention?

Primary prevention involves intervening before the onset of disease,

specifically by preventing infection with high-risk human papillomavirus
(HPV), which causes over 99% of cervical cancer cases.

A. HPV Vaccination

1. Types of Vaccines:

 Bivalent vaccine (Cervarix): Targets HPV types 16 and 18 (high-risk

oncogenic types).
 Quadrivalent vaccine (Gardasil): Targets HPV 6, 11, 16, and 18 (adds
protection against genital warts).
 Nonavalent vaccine (Gardasil 9): Targets 9 HPV types—6, 11, 16, 18,
31, 33, 45, 52, and 58—offering broader coverage.

2. Mechanism of Action:

 Vaccines contain virus-like particles (VLPs) that mimic HPV capsid

proteins.
 They elicit a strong humoral immune response but do not contain
viral DNA, so they are non-infectious.

3. Recommended Age:

 Ideal age: 9–14 years (before sexual debut).

  Can be given up to 26 years of age, and in some settings, even up to 45
years.
 Two-dose schedule for ages 9–14 years.
 Three-dose schedule for individuals >15 years or immunocompromised.

4. Efficacy:

 Prevents up to 90% of cervical cancers if administered before HPV

exposure.
 Reduces incidence of CIN 2/3, genital warts, and HPV-related
oropharyngeal cancers.

5. Global Implementation:

 WHO recommends nationwide HPV vaccination programs, especially in

low- and middle-income countries.
 GAVI-supported initiatives are expanding access in resource-limited
settings.

B. Sexual Health Education and Safe Practices

 Delay initiation of sexual activity reduces risk of early HPV exposure.

 Use of condoms may provide partial protection, though HPV can be
transmitted via skin-to-skin contact.
 Reducing the number of sexual partners lowers the likelihood of HPV
transmission.
 Partner vaccination (especially boys) helps reduce community
transmission.

C. Lifestyle Modifications

 Avoid tobacco use: Smoking suppresses local immunity and increases

HPV persistence.
  Good genital hygiene: May reduce secondary infections and
inflammation that promote carcinogenesis.

2. SECONDARY PREVENTION

What is Secondary Prevention?

Secondary prevention aims at early detection and treatment of

precancerous lesions or carcinoma in situ, before they progress to invasive
disease. It significantly reduces morbidity and mortality.

A. Cervical Cancer Screening Methods

1. Pap Smear (Cytology-Based Screening)

 Detects cellular abnormalities in cervical epithelial cells.

 Screening should begin at age 21 and continue every 3 years.
 Liquid-based cytology improves accuracy and sample adequacy.

2. HPV DNA Testing

 Detects high-risk HPV genotypes before cytological changes occur.

 More sensitive than cytology but less specific.
 Starting at age 30, co-testing with Pap smear is preferred every 5 years.

3. Visual Inspection with Acetic Acid (VIA)

 3–5% acetic acid applied to cervix → acetowhite lesions suggest

dysplasia.
 Used in resource-limited settings.
 Immediate treatment can be given (screen-and-treat approach).

B. Management of Positive Screening

 ASCUS or LSIL → Repeat Pap/HPV or proceed to colposcopy.

  HSIL or HPV-16/18 positive → Immediate colposcopy and biopsy.
 CIN 2/3 confirmed → Treated with LEEP, cold knife conization, or
cryotherapy.

3. TERTIARY PREVENTION

What is Tertiary Prevention?

Tertiary prevention focuses on limiting complications, recurrence, and

disability in patients already diagnosed and treated for cervical cancer. It
includes clinical care, rehabilitation, and follow-up.

A. Treatment of Precancerous Lesions (CIN)

 CIN I (Low-grade): Often regresses spontaneously. Monitored with repeat

cytology.
 CIN II/III (High-grade): Requires excisional or ablative procedures:
o LEEP (Loop Electrosurgical Excision Procedure)
o Cold knife conization
o Cryotherapy (freezing abnormal tissue)
o Laser ablation

B. Treatment of Invasive Cancer

 Early-stage: Surgery (hysterectomy or trachelectomy)

 Locally advanced: Chemoradiation
 Advanced disease: Systemic therapy, targeted therapy, immunotherapy

C. Post-Treatment Surveillance

 Regular pelvic examinations every 3–6 months for the first 2 years.
 Annual Pap smears or HPV testing (depending on prior treatments).
 Imaging as indicated for symptoms or recurrence risk.
  Psychosocial support, pain management, and palliative care are
essential for advanced cases.

D. Health System Strengthening

 Train healthcare workers in screening, colposcopy, and treatment.

 Ensure access to vaccination, cytology labs, pathology services, and
oncology centers.
 Public awareness campaigns to promote screening and vaccine uptake.

Esophageal Cancer

Esophageal cancer is a malignant tumor that develops in the tissues of

the esophagus, the muscular tube responsible for carrying food and liquids
from the throat to the stomach. It arises when the normal epithelial cells lining
the esophagus undergo genetic mutations, lose normal growth control, and
proliferate uncontrollably, forming an invasive neoplasm. Esophageal cancer is
often aggressive, with a tendency for early local invasion into surrounding
structures and early lymphatic spread, making early detection crucial for
survival.

Anatomy of the Esophagus

The esophagus is a 25–30 cm long muscular tube that extends from the
pharynx to the stomach, traversing the neck, thorax, and diaphragm. It serves
as the conduit for swallowed food and liquids. It begins at the level of the
cricoid cartilage (C6 vertebra) and ends at the gastroesophageal junction,
where it meets the stomach.

1. Structure and Sphincters

  Pharynx to Upper Esophageal Sphincter (UES):

o The UES is composed mainly of the cricopharyngeal muscle.

o Function: Remains contracted to prevent air from entering the

esophagus during respiration. It relaxes during swallowing to allow
food passage.

 Lower Esophageal Sphincter (LES):

o Located at the junction between the esophagus and stomach.

o Function: Remains tightly closed between meals to prevent acid

reflux and gastric contents from entering the esophagus.

o Relaxes during swallowing.

2. Layers of the Esophageal Wall

The esophageal wall is organized into four concentric layers, each with
distinct structure and function:

A. Mucosa

 Innermost layer, directly in contact with ingested food.

 Functions:

o Protects the esophagus from mechanical friction due to food

particles.

o Provides a barrier to pathogens and minor chemical irritants.

 Components:

1. Stratified squamous epithelium:

 Non-keratinized.
  Provides mechanical protection rather than absorption.

2. Lamina propria:

 Connective tissue layer containing blood vessels, lymphatics,

and immune cells.

3. Muscularis mucosae:

 Thin smooth muscle layer aiding local mucosal movement.

B. Submucosa

 Contains:

o Loose connective tissue.

o Esophageal glands that secrete mucus for lubrication.

o Blood vessels, lymphatics, and nerve plexuses (Meissner’s plexus).

C. Muscular Layer (Muscularis Propria)

 Composed of two muscle layers:

o Inner circular layer.

o Outer longitudinal layer.

 Muscle type varies:

o Upper third: Skeletal muscle (voluntary).

o Middle third: Mixed skeletal and smooth muscle.

o Lower third: Smooth muscle (involuntary).

  Coordinates peristaltic contractions that propel food to the stomach.

D. Adventitia

 Outermost connective tissue layer.

 Lacks a serosal covering (unlike most gastrointestinal organs), which

makes the esophagus more vulnerable to local tumor invasion.

3. Gastroesophageal Junction (GEJ)

 At the lower end, the squamous epithelium transitions abruptly to

columnar gastric epithelium—this is known as the Z-line or
squamocolumnar junction.

 Abnormal changes at this junction can lead to Barrett’s esophagus, a

precursor to adenocarcinoma.

How Esophageal Cancer Develops

Esophageal cancer does not arise suddenly; it follows a progressive,

multistep sequence of changes involving chronic irritation, cellular injury,
genetic alterations, and ultimately malignant transformation. These steps differ
slightly depending on whether the cancer develops as squamous cell
carcinoma or adenocarcinoma, but the fundamental mechanism—persistent
damage leading to genomic instability—remains the same.
1. Chronic Mucosal Injury (Initiation Stage)

The esophageal lining is normally composed of stratified squamous

epithelium, which provides mechanical protection but has limited resistance
to chemical injury. Continuous exposure to harmful substances leads to
repetitive epithelial damage, causing inflammation, regeneration, and
cellular stress.

Common injurious factors:

 Gastroesophageal reflux disease (GERD): Repeated exposure to acidic

gastric contents injures the lower esophageal mucosa.

 Alcohol and tobacco: Both are strong irritants and contain carcinogens
that damage DNA directly.

 Caustic ingestion: Accidental or intentional ingestion of lye or corrosives

causes long-term mucosal scarring and precancerous changes.

 Nutritional deficiencies: Lack of antioxidants (vitamins A, C, selenium)

reduces mucosal protection.

 Thermal injury: Habitual consumption of very hot beverages causes

chronic microtrauma.

This persistent injury sets the stage for abnormal cell growth and mutations.

2. Cellular Changes (Precancerous Stage)

When epithelial cells undergo continuous damage, they begin to divide

more rapidly to replace injured cells. Increased replication leads to DNA
replication errors and abnormal cell structures.

For Squamous Cell Carcinoma:

  Chronic irritation → Squamous hyperplasia (increased cell layers).

 Development of dysplasia: Cells show abnormal size, shape, and

organization.

 Carcinoma in situ: Dysplastic cells occupy the entire epithelial

thickness but have not invaded the basement membrane.

 Once the abnormal cells breach the basement membrane and infiltrate
the underlying stroma, the lesion becomes invasive squamous cell
carcinoma.

For Adenocarcinoma:

 GERD-induced injury causes squamous epithelium to transform into

intestinal-type columnar epithelium in an adaptive process called
Barrett’s esophagus.

 Barrett’s esophagus cells are more resistant to acid but genetically

unstable.

 Over time, they accumulate dysplastic changes:

o Low-grade dysplasia → High-grade dysplasia → Adenocarcinoma.

 This sequence can take years, offering a window for detection and
treatment.

3. Genetic and Molecular Alterations

Persistent injury and repeated cell turnover lead to genetic mutations

and epigenetic changes that disrupt normal growth regulation:

Tumor Suppressor Gene Inactivation

 p53 mutation: Leads to failure in DNA damage repair and prevention of

apoptosis. Damaged cells survive instead of dying.
  p16 (CDKN2A) loss: Removes control over the G1-to-S phase checkpoint
in the cell cycle, allowing unchecked proliferation.

Oncogene Activation

 Cyclin D1 amplification: Drives continuous cell cycle progression.

 EGFR (Epidermal Growth Factor Receptor) overexpression: Promotes

uncontrolled growth signaling.

 HER2 amplification: In adenocarcinomas, HER2 promotes aggressive

tumor behavior.

DNA Damage and Carcinogen Effects

 Oxidative stress from chronic inflammation generates reactive oxygen

species (ROS), which break DNA strands.

 Nitrosamines (from tobacco, preserved foods) form DNA adducts,

increasing mutational load.

4. Tumor Progression and Invasion

Once genetic stability is lost:

 Tumor cells become immortal (reactivation of telomerase).

 They gain invasive capabilities by secreting enzymes (matrix

metalloproteinases) that degrade the basement membrane and
extracellular matrix.

 They stimulate angiogenesis (via VEGF) to secure their own blood

supply.

 Cells enter lymphatic vessels (abundant in the esophagus) → early

lymph node metastasis.

 Eventually, cells spread hematogenously to the liver, lungs, and bones.

Summary Flow

Chronic Injury → DNA Damage → Dysplasia → Carcinoma in situ →

Genetic Instability → Invasive Cancer → Angiogenesis and Metastasis

Types of Esophageal Cancer

Esophageal cancer is classified primarily based on the histological type

of the cells from which it originates. Each type has distinct epidemiology, risk
factors, anatomical distribution, clinical behavior, and treatment
implications. The major categories include Squamous Cell Carcinoma (SCC),
Adenocarcinoma, and several rare histological subtypes.

A. Squamous Cell Carcinoma (SCC)

1. Origin & Histology

 SCC arises from the stratified squamous epithelium that lines most of
the esophagus.

 Microscopy shows keratinizing malignant cells, intercellular bridges,

and variable degrees of differentiation.

 Tumor growth is often circumferential, leading to luminal narrowing.

2. Epidemiology

 Historically the most common type worldwide, particularly in:

o East Asia (China, Japan)

o Parts of Africa

o Middle East

 In Western countries, its incidence has declined due to lifestyle changes,

while adenocarcinoma rates have increased.
3. Anatomical Location

 Frequently develops in the middle third of the esophagus.

 Can also occur in the upper third.

4. Risk Factors

SCC is strongly associated with environmental, dietary, and lifestyle

exposures:

 Tobacco smoking and alcohol consumption: These act synergistically

to damage DNA and promote carcinogenesis.

 Nitrosamines: Found in preserved foods (e.g., pickled vegetables, salted

fish).

 Thermal injury: Regular intake of very hot beverages (e.g., tea) causes
chronic epithelial damage.

 Nutritional deficiencies: Low intake of fruits, vegetables, and

micronutrients (vitamin A, selenium).

 Pre-existing esophageal disorders:

o Achalasia (due to stasis and fermentation of food)

o Caustic strictures

o Plummer-Vinson syndrome (iron deficiency, esophageal webs)

5. Biological Behavior

 Tends to spread:

o Longitudinally along the esophageal wall.

o Early invasion into adjacent mediastinal structures (due to lack

of serosa).
 o Early lymphatic dissemination to cervical, mediastinal, and
abdominal nodes.

B. Adenocarcinoma

1. Origin & Histology

 Arises from glandular (columnar) epithelium.

 Most cases occur in the context of Barrett’s esophagus, where the

normal squamous epithelium is replaced by intestinal-type columnar
cells due to chronic acid exposure.

 Histology shows malignant glandular structures producing mucin.

2. Epidemiology

 Now the most common type in Western countries (United States, UK,
Australia).

 Increasing incidence is linked to rising obesity and GERD prevalence.

3. Anatomical Location

 Primarily affects the distal (lower) third of the esophagus and the
gastroesophageal junction (GEJ).

4. Risk Factors

 Chronic GERD: The major risk factor.

 Barrett’s esophagus: Increases adenocarcinoma risk by 30–40 times.

 Obesity: Causes higher intra-abdominal pressure → more acid reflux.

 Smoking: Adds synergistic risk.

 Male gender, Caucasian ethnicity: Higher susceptibility.

  Genetic alterations: p53 mutations, HER2 amplification.

5. Biological Behavior

 Rapidly infiltrates surrounding tissues.

 High rate of lymph node metastasis even in early stages.

 Associated with poorer outcomes compared to early-detected SCC due to

late diagnosis.

C. Rare Types of Esophageal Cancer

Though uncommon, several other malignancies can arise in the esophagus:

1. Small Cell Carcinoma

 Aggressive neuroendocrine tumor.

 Resembles small cell lung carcinoma histologically.

 Rapid growth and early metastasis.

 Treated mainly with chemoradiotherapy rather than surgery.

2. Sarcomas (e.g., Leiomyosarcoma)

 Originate from smooth muscle cells in the esophageal wall.

 Rare; present as large intraluminal masses.

 Surgery is the main treatment.

3. Primary Esophageal Lymphoma

 Very rare; usually associated with immunodeficiency (e.g., HIV,

transplant).

 Treated primarily with chemotherapy ± radiation rather than surgery.

4. Malignant Melanoma
  Extremely rare primary tumor; may represent metastasis from cutaneous
melanoma.

 Very aggressive with poor prognosis.

Causes of Esophageal Cancer

Esophageal cancer is a multifactorial disease, meaning it develops due

to a combination of environmental exposures, lifestyle habits, chronic
medical conditions, and genetic predispositions. The causative factors differ
between the two main histological types: Squamous Cell Carcinoma (SCC) and
Adenocarcinoma.

A. Causes of Squamous Cell Carcinoma (SCC)

SCC arises from the squamous epithelium that lines most of the
esophagus. Its development is strongly linked to chronic epithelial irritation
and exposure to chemical and thermal carcinogens.

1. Tobacco and Alcohol – Synergistic Carcinogens

 Tobacco smoke contains polycyclic aromatic hydrocarbons,

nitrosamines, and other DNA-damaging carcinogens.

 Alcohol (ethanol) is metabolized into acetaldehyde, a carcinogenic

compound that damages DNA and proteins.

 Combined use of tobacco and alcohol dramatically increases SCC risk

due to:

o Enhanced mucosal injury.

o Increased production of reactive oxygen species (ROS).

o Impaired DNA repair mechanisms.

  Populations with high rates of heavy drinking and smoking show SCC
incidence rates up to 100 times higher than abstinent populations.

2. Consumption of Very Hot Beverages

 Chronic thermal injury from repeatedly drinking beverages above 65–

70°C (e.g., hot tea, coffee, maté) causes:

o Direct epithelial burns.

o Recurrent inflammation.

o Accelerated cell turnover → higher risk of mutations.

 Epidemiological studies in Iran, China, and South America show strong

associations between this habit and SCC.

3. Nutritional Deficiencies

 Low intake of antioxidant-rich foods (fruits, vegetables, vitamins A, C,

E, selenium) reduces the esophagus’s ability to neutralize free radicals.

 Diets high in nitrosamines (from smoked or pickled foods) add

mutagenic load.

 In some endemic areas, protein-calorie malnutrition further weakens

mucosal defense.

4. Chronic Esophageal Irritation

 Achalasia: Poor esophageal motility → food stasis → fermentation →

chronic irritation and carcinogen formation.

 Caustic injury: Accidental or suicidal ingestion of lye or strong alkalis

leads to strictures that increase long-term SCC risk (can appear decades
later).
  Esophageal strictures: Repeated trauma and inflammation predispose
to dysplasia.

 Plummer-Vinson syndrome: Iron deficiency causes mucosal atrophy

and esophageal webs → SCC susceptibility.

5. Genetic Predisposition

 Tylosis (Howel-Evans syndrome): A rare autosomal dominant disorder

causing palmoplantar keratoderma and nearly 100% lifetime risk of
esophageal SCC.

 Fanconi anemia: A DNA repair defect leading to chromosomal instability

→ high SCC incidence.

B. Causes of Adenocarcinoma

Adenocarcinoma arises from glandular (columnar) epithelium, most

commonly in the lower third of the esophagus. Its causes are closely related
to chronic acid reflux and conditions that promote Barrett’s esophagus.

1. Chronic GERD → Barrett’s Esophagus

 Long-standing gastroesophageal reflux disease (GERD) repeatedly

exposes the lower esophagus to gastric acid and bile salts.

 Persistent acid injury triggers metaplasia: squamous cells are replaced

by intestinal-type columnar epithelium (Barrett’s esophagus).

 Barrett’s epithelium is genetically unstable and prone to dysplasia →

adenocarcinoma.

 Individuals with long-segment Barrett’s esophagus have a 30–40-fold

higher risk of developing adenocarcinoma.
2. Obesity

 Central (abdominal) obesity increases intra-abdominal pressure,

causing frequent acid reflux.

 Adipose tissue secretes pro-inflammatory cytokines (e.g., TNF-α, IL-6)

that promote carcinogenesis.

 Obesity is a major factor in the rapid rise of adenocarcinoma cases in

Western countries.

3. Smoking

 Cigarette smoking contributes to adenocarcinoma development by:

o Increasing GERD severity.

o Adding direct DNA-damaging carcinogens.

 Even after quitting, the risk remains elevated for several years.

4. Genetic Factors

 Certain genetic mutations make Barrett’s epithelium more prone to

malignant transformation:

o TP53 mutation: Leads to defective DNA damage repair.

o CDKN2A (p16) inactivation: Allows uncontrolled cell cycle

progression.

o Other pathways: HER2 amplification, EGFR overexpression.

Signs and Symptoms of Esophageal Cancer

Esophageal cancer is often called a “silent disease” in its early stages

because it produces no noticeable symptoms until the tumor has grown
significantly. By the time symptoms develop, the disease is usually locally
advanced or has already spread, which contributes to its poor prognosis.
Below is a detailed explanation of each sign and symptom.

A. Why Symptoms Appear Late

 The esophageal lumen (internal passage) has a relatively large diameter

(about 2–3 cm).

 Tumors can grow circumferentially but must obstruct about 50–75% of

the lumen before causing swallowing difficulties.

 The esophagus has no serosa and few pain receptors, so early tumors
do not cause pain or obvious discomfort.

 As a result, initial cancer growth can go unnoticed for months or even

years.

B. Early Symptoms

1. Progressive Dysphagia (Difficulty Swallowing)

 Most common initial symptom.

 Initially affects solid foods (meat, bread, rice) because they require a
larger lumen.

 As the tumor enlarges and narrows the esophageal passage, patients

eventually struggle with semisolids and then liquids.

 In very advanced disease, saliva itself becomes hard to swallow.

 Dysphagia progression is typically gradual (over weeks to months), which

helps distinguish malignancy from benign strictures.

2. Odynophagia (Painful Swallowing)

 Occurs when the tumor causes ulceration or inflammation of the

mucosa.
  The pain may be sharp or burning and is felt retrosternally (behind the
breastbone) or in the upper chest.

 Odynophagia often leads to reduced oral intake, worsening

malnutrition.

C. Advanced Symptoms

As the tumor enlarges or spreads, additional systemic and local symptoms

develop:

1. Unintentional Weight Loss

 One of the hallmark systemic symptoms.

 Caused by:

o Reduced food intake due to dysphagia and odynophagia.

o Cancer-related cachexia: Tumors release cytokines (TNF-α, IL-1,

IL-6) that increase metabolism and break down muscle and fat.

 Weight loss can be rapid and significant, often >10% of body weight.

2. Chest or Back Pain

 Indicates tumor invasion into surrounding structures such as:

o Mediastinum

o Aorta

o Pleura or vertebral bodies

 Pain is often dull and persistent, not relieved by rest or antacids.

3. Regurgitation of Undigested Food

  Occurs when the esophagus becomes severely obstructed.

 Food can stagnate above the tumor, leading to:

o Regurgitation hours after eating.

o Foul-smelling breath.

o Risk of aspiration.

4. Hoarseness of Voice

 Results from invasion or compression of the recurrent laryngeal

nerve (branch of the vagus nerve) in the upper chest.

 Leads to:

o Weak, breathy voice.

o Sometimes associated with coughing while drinking fluids (nerve

damage affects vocal cord closure).

5. Chronic Cough and Aspiration Pneumonia

 Caused by:

o Formation of a tracheoesophageal fistula (abnormal connection

between esophagus and trachea).

o This allows swallowed food or saliva to enter the airway.

 Leads to:

o Frequent coughing during meals.

o Recurrent aspiration pneumonia.

o Severe respiratory complications.

6. Anemia and Fatigue

 Chronic bleeding from an ulcerated tumor surface causes:

o Iron-deficiency anemia.

o Symptoms: Pale skin, weakness, dizziness, and persistent fatigue.

 Often overlooked as they develop gradually.

Diagnosis of Esophageal Cancer – Detailed Explanation

Diagnosing esophageal cancer involves detecting the primary tumor,

confirming its histological type, determining the depth of invasion, and
assessing local and distant spread (staging). Accurate diagnosis is crucial
because it dictates the treatment plan, surgical eligibility, and prognosis.

A. Initial Evaluation

1. Upper Endoscopy (Esophagogastroduodenoscopy – EGD)

 Purpose:

o Direct visualization of the esophageal mucosa.

o Identification of suspicious lesions, their size, length, and exact

location.

 Procedure:

o A flexible endoscope equipped with a light and camera is passed

through the mouth into the esophagus, stomach, and duodenum.

 Findings:
 o Early tumors may appear as subtle mucosal irregularities,
nodules, or flat lesions.

o Advanced tumors present as ulcerated masses, circumferential

strictures, or exophytic (outward-growing) lesions.

 Biopsy:

o Multiple tissue samples are taken for histological confirmation.

o At least 6–8 biopsies are recommended from different parts of the

lesion to avoid false negatives.

2. Histopathology

 Goal: Confirms:

o Type: Squamous cell carcinoma, adenocarcinoma, or rare

variants.

o Grade: Degree of differentiation (well, moderately, or poorly

differentiated).

o Additional markers: HER2 overexpression (important for targeted

therapy in adenocarcinoma), PD-L1 levels (for immunotherapy).

 Special stains / Immunohistochemistry:

o Cytokeratin profiles help differentiate primary esophageal tumors

from metastases.

B. Staging Work-Up

After confirming cancer histology, staging determines the tumor depth

(T), lymph node involvement (N), and distant metastasis (M)—following the
AJCC TNM classification.

1. Endoscopic Ultrasound (EUS)

  Purpose: Most accurate test for assessing tumor depth (T stage) and
regional lymph node involvement.

 Method:

o An endoscope with an ultrasound probe is inserted into the

esophagus.

o Provides high-resolution images of the esophageal wall layers and

adjacent structures.

 Advantages:

o Differentiates between T1 (mucosa/submucosa), T2 (muscle), T3

(adventitia), and T4 (adjacent organs).

o Allows fine-needle aspiration (FNA) of suspicious lymph nodes.

2. CT Scan (Chest, Abdomen, Pelvis)

 Purpose: Evaluates:

o Tumor spread beyond the esophagus.

o Involvement of mediastinum, lungs, liver, adrenal glands.

o Regional and distant lymph nodes.

 Limitations: Less sensitive for small metastases compared to PET-CT.

3. PET-CT Scan (Positron Emission Tomography + Computed Tomography)

 Purpose: Detects metabolically active lesions throughout the body.

 Method:

o A radioactive glucose analog (FDG) is injected.

 o Cancer cells (which have high metabolic rates) absorb more tracer
and show as “hot spots.”

 Benefit: Identifies distant metastases not visible on CT, preventing

unnecessary surgery.

 Limitation: May produce false positives (e.g., inflammation also takes up

tracer).

4. Bronchoscopy

 Indication:

o Tumors located in the upper or middle third of the esophagus.

o To check for tracheal or bronchial invasion, which changes

surgical planning.

 Findings:

o Airway compression, fistula formation, or mucosal invasion.

C. Laboratory Tests

1. Complete Blood Count (CBC)

 Detects:

o Anemia due to chronic tumor bleeding.

o Abnormal white cell or platelet counts indicating bone marrow

involvement or paraneoplastic effects.

2. Liver Function Tests (LFTs)

 Elevated enzymes (ALT, AST, ALP) may indicate liver metastases.

 Important for chemotherapy planning (dose adjustments).

Screening of Esophageal Cancer

Unlike some other cancers (e.g., cervical or breast cancer), routine

population-wide screening for esophageal cancer is not universally
recommended because:

 Incidence is relatively low in most regions.

 Effective, cost-efficient mass screening methods are lacking.

 Most cases occur in advanced stages despite existing tools.

However, targeted screening is valuable for high-risk individuals or

populations living in areas where esophageal cancer is endemic (e.g., parts of
China, Iran, South Africa, India).

A. Who Requires Screening?

1. Patients with Barrett’s Esophagus

o Barrett’s is a known precursor to adenocarcinoma.

o Surveillance endoscopy every 3–5 years is recommended.

o High-grade dysplasia requires closer monitoring (every 6–12

months or earlier intervention).

2. Strong Family History

o Those with first-degree relatives diagnosed with esophageal cancer.

3. Long-standing GERD with Additional Risk Factors

o Chronic reflux + obesity + male sex + Caucasian ethnicity → higher

adenocarcinoma risk.

4. Genetic Syndromes

o Tylosis, Fanconi anemia → early screening initiation.

B. Screening Techniques

1. Endoscopic Examination – Gold Standard

o Detects early mucosal abnormalities, dysplastic lesions, or small

tumors.

o Biopsies taken for histopathological analysis.

2. Advanced Imaging Enhancements

o Chromoendoscopy: Special dyes (e.g., Lugol’s iodine) highlight

abnormal mucosa.

o Narrow-Band Imaging (NBI): Uses specific light wavelengths to

enhance vascular patterns of dysplastic tissue.

3. Cytology Sampling (Non-Endoscopic Methods)

o Research techniques like balloon or sponge devices collect

esophageal cells for cytological screening.

o Less invasive and potentially suitable for mass screening in high-

prevalence regions.

Goal of Screening:

 Detect precancerous changes (dysplasia) or early-stage tumors that

can be treated endoscopically before they become invasive.

Treatment of Esophageal Cancer – Detailed and Technical Explanation

Treatment selection depends on tumor stage, histological type (SCC or

adenocarcinoma), location, patient’s overall health, and goals (curative vs.
palliative). Management is multidisciplinary, involving surgical oncology,
medical oncology, radiation oncology, gastroenterology, and nutrition
support teams.
A. Early-Stage Disease (T1a, Node-Negative)

 Endoscopic Mucosal Resection (EMR): Removes superficial tumors

confined to the mucosa.

 Endoscopic Submucosal Dissection (ESD): More advanced technique

allowing removal of larger, en bloc lesions.

 Ablation Therapy:

o Radiofrequency ablation (RFA): Destroys Barrett’s dysplasia or

residual abnormal mucosa after EMR.

o Prevents progression to invasive adenocarcinoma.

Advantages: Minimally invasive, organ-preserving, rapid recovery.

B. Resectable Locally Advanced Disease (Stages IIA–III)

These tumors invade deeper wall layers or have regional lymph node
involvement but no distant metastasis.

 Standard of Care: Neoadjuvant chemoradiotherapy (CROSS protocol:

carboplatin + paclitaxel + radiation) followed by surgery.

 Surgical Options:

o Ivor Lewis Esophagectomy: Two-stage transthoracic approach

(abdominal + thoracic).

o Transhiatal Esophagectomy: Abdominal + neck incision; avoids

thoracotomy.

o Minimally Invasive Esophagectomy (MIE):

Laparoscopic/thoracoscopic approach; fewer complications.

 Lymphadenectomy: Removal of regional lymph nodes to ensure

complete staging and reduce recurrence.
C. Unresectable or Advanced Disease

For tumors invading critical structures (aorta, trachea) or with distant

metastases:

1. Definitive Chemoradiotherapy (CCRT):

o Combined cisplatin + 5-FU + radiation.

o Goal: Local control and symptom relief.

2. Systemic Chemotherapy (for metastases):

o Regimens include 5-FU + cisplatin or carboplatin + paclitaxel.

3. Targeted Therapy:

o Trastuzumab: For HER2-positive adenocarcinoma.

o Ramucirumab: Anti-VEGFR2 antibody for second-line therapy.

4. Immunotherapy:

o PD-1 inhibitors (Nivolumab, Pembrolizumab): For PD-L1-positive

advanced cancers.

o Improves survival in refractory cases.

D. Palliative Management

Goal: Improve quality of life and relieve distressing symptoms (especially

dysphagia).

 Esophageal stent placement: Restores swallowing ability.

 Palliative radiation: Reduces tumor size and pain.

 Laser therapy or photodynamic therapy: Clears obstructing lesions.

  Nutritional support: Feeding gastrostomy or jejunostomy prevents
malnutrition.

Prevention of Esophageal Cancer – Detailed Explanation

Because esophageal cancer is often diagnosed late, prevention is critical

and divided into three levels:

A. Primary Prevention (Avoid Cancer Initiation)

 Lifestyle modifications:

o Quit tobacco (smoking and chewing forms).

o Avoid excessive alcohol.

o Avoid very hot beverages (>65°C) to prevent chronic mucosal

burns.

 Dietary improvements:

o Increase fruits, vegetables, antioxidants, selenium, and

vitamins.

o Reduce consumption of nitrosamine-rich preserved foods.

 Maintain a healthy weight: Lowers GERD risk.

 Manage GERD early: Reduces Barrett’s risk.

B. Secondary Prevention (Detect and Treat Early Lesions)

 Surveillance endoscopy in patients with Barrett’s esophagus or

achalasia.

 Targeted screening in high-risk geographic areas.

 Treatment of premalignant lesions:

 o Ablation or endoscopic removal of Barrett’s dysplasia.

o Dilatation or surgical correction for strictures in caustic injury or

achalasia.

C. Tertiary Prevention (Prevent Recurrence or Complications)

 Regular follow-up after treatment:

o Endoscopy every 6–12 months initially.

o Imaging for recurrence detection.

 Continued lifestyle modification:

o Avoid risk factors that can trigger second primary cancers.

 Nutritional rehabilitation and psychosocial support to improve long-term

survival.

Diagnosis – Biomarkers

Definition and Importance of Biomarkers in Cancer Diagnosis

Biomarkers are biological indicators—molecules, genes, proteins, or

cellular characteristics—that can be objectively measured and evaluated as
signs of normal biological processes, pathogenic processes, or responses to
a therapeutic intervention.

In the context of cancer diagnosis:

 They are not only used to detect the presence of malignancy but also
to provide information about tumor type, grade, stage, aggressiveness,
and treatment response.
 Biomarkers have become integral to precision medicine, allowing
physicians to move beyond one-size-fits-all approaches to personalized
oncology.
Role of Biomarkers in Diagnostic Pathway

A. Initial Detection

 Identify abnormal tissue origin (e.g., melanoma vs epithelial carcinoma).

 Distinguish between benign, premalignant, and malignant lesions.

B. Tumor Characterization

 Classify cancer type (e.g., adenocarcinoma vs squamous cell carcinoma).

 Identify molecular signatures that are characteristic of specific
subtypes.

C. Prognosis

 Some biomarkers correlate with tumor growth rate, metastatic

potential, and overall survival.

D. Predictive Use

 Determine which patients will benefit from targeted therapies or

immunotherapies (e.g., HER2, PD-L1).

E. Monitoring and Surveillance

 Biomarkers can be measured serially to:

o Evaluate treatment response.
o Detect recurrence earlier than imaging.

Types of Biomarkers

Biomarkers are broadly classified by their function:

A. Diagnostic Biomarkers
  Used to detect cancer or confirm its presence.
 Example:
o S-100, HMB-45, Melan-A, SOX10 → Identify melanocytic origin
(melanoma).
o Ber-EP4 → Differentiates basal cell carcinoma (positive) from
squamous cell carcinoma (negative).
o p16INK4a → Indicates HPV-associated oral and cervical cancers.

B. Prognostic Biomarkers

 Provide information on likely disease course regardless of treatment.

 Example:
o Ki-67 → High expression indicates a fast-growing, aggressive
tumor.
o TP53 mutation → Associated with poor prognosis in multiple
cancers.

C. Predictive Biomarkers

 Identify which therapies are likely to work.

 Example:
o HER2 overexpression → Predicts benefit from trastuzumab in
esophageal and breast cancers.
o PD-L1 expression → Indicates eligibility for immune checkpoint
inhibitors (e.g., pembrolizumab).

D. Molecular/Genetic Biomarkers

 Detect mutations, rearrangements, amplifications, or deletions:

o BRAF V600E mutation → Melanoma targeted with BRAF
inhibitors.
o EGFR mutation, ALK/ROS1 fusions → Lung adenocarcinoma
therapies.
 o TERT promoter mutations → Associated with aggressive
melanoma and SCC.

E. Circulating Biomarkers

 Found in blood, saliva, or other body fluids:

o Circulating tumor DNA (ctDNA): Detects tumor mutations non-
invasively.
o Circulating tumor cells (CTCs): Reflect tumor burden and
metastatic potential.

Examples of Important Biomarkers by Cancer Type

Biomarkers differ depending on the type of cancer, and each has a

specific role in diagnosis, prognosis, and therapeutic planning. Below is an
expanded, in-depth explanation of the listed biomarkers, their molecular
functions, detection methods, and clinical significance.

1. Skin Cancer Biomarkers

Key Biomarkers:

 S-100:
o Calcium-binding protein present in melanocytes.
o Role: Most sensitive marker for melanoma diagnosis but not highly
specific (also expressed in nerve tissue and Langerhans cells).
 HMB-45 (Human Melanoma Black-45):
o Recognizes gp100 antigen in melanosomes.
o Role: Highly specific for melanocytic tumors; helps distinguish
melanoma from other cancers.
 Melan-A (MART-1):
o Melanosomal differentiation antigen.
 o Role: Used in immunohistochemistry to confirm melanocyte
lineage.
 SOX10:
o Nuclear transcription factor critical for neural crest and
melanocyte development.
o Role: Sensitive and specific for melanoma, including desmoplastic
variants where HMB-45 may be negative.
 BRAF Mutation (V600E):
o Activating mutation in the MAPK pathway → uncontrolled cell
proliferation.
o Role: Target for BRAF inhibitors (vemurafenib, dabrafenib) in
metastatic melanoma.
 TERT Promoter Mutations:
o Activate telomerase → cellular immortality.
o Role: Associated with aggressive melanoma.
 NRAS Mutations:
o Drive uncontrolled cell signaling.
o Role: Important for prognosis; influences therapy selection when
BRAF is negative.

2. Lung Cancer Biomarkers

Key Biomarkers:

 EGFR Mutations:
o Epidermal growth factor receptor mutations activate tyrosine
kinase signaling.
o Role: Patients benefit from EGFR inhibitors (erlotinib, gefitinib,
osimertinib).
 ALK and ROS1 Rearrangements:
o Gene fusions that activate oncogenic pathways.
 o Role: Sensitive to ALK/ROS1 inhibitors (crizotinib, alectinib,
lorlatinib).
 KRAS Mutations:
o Most common mutation in non-small cell lung cancer (NSCLC).
o Role: Historically considered untargetable but now treated with
KRAS-G12C inhibitors (sotorasib).
 PD-L1 Expression:
o Programmed death-ligand 1 overexpression on tumor cells.
o Role: Predicts response to immune checkpoint inhibitors
(pembrolizumab, nivolumab).
 MET Amplification / Exon 14 Skipping:
o Activates growth pathways.
o Role: Targeted by MET inhibitors (capmatinib, tepotinib).
 RET Rearrangements:
o Less common but treatable with RET inhibitors (selpercatinib,
pralsetinib).

3. Oral Cancer Biomarkers

Key Biomarkers:

 p16 (INK4a):
o Surrogate marker for high-risk HPV infection.
o Role: p16-positive tumors (HPV-associated) often have a better
prognosis and respond better to radiation/chemotherapy.
 Cyclin D1:
o Cell cycle regulatory protein (G1/S transition).
o Role: Overexpression indicates aggressive tumor behavior and
poor prognosis.
 Ki-67:
o Nuclear protein associated with cellular proliferation.
 o Role: High Ki-67 index correlates with rapid growth and poor
outcomes.
 TP53 Mutation:
o Loss of tumor suppressor function.
o Role: Linked to genomic instability and worse survival rates.

4. Esophageal Cancer Biomarkers

Key Biomarkers:

 HER2 (ERBB2):
o Growth factor receptor overexpressed in some adenocarcinomas.
o Role: HER2-positive patients benefit from trastuzumab-based
therapy.
 PD-L1 Expression:
o Predicts response to immunotherapy.
 TP53 Mutations:
o Present in >70% of esophageal cancers.
o Role: Associated with carcinogenesis and poor prognosis.
 VEGF (Vascular Endothelial Growth Factor):
o Stimulates angiogenesis.
o Role: Target for anti-angiogenic therapies (ramucirumab).

5. Cervical Cancer Biomarkers

Key Biomarkers:

 HPV DNA (High-Risk Types 16, 18):

o HPV infection is the primary cause of cervical cancer.
o Role: Molecular HPV DNA testing is used for screening and early
diagnosis.
  E6/E7 mRNA:
o Oncogenic viral transcripts that inactivate p53 and Rb tumor
suppressors.
o Role: Indicates active infection and higher risk for progression to
cancer.
 p16INK4a:
o Overexpressed due to HPV E7 activity.
o Role: Serves as a biomarker for transforming HPV infections and
early malignant changes.

Techniques Used to Detect Biomarkers

Detection of biomarkers involves specialized laboratory techniques that

analyze tissue, blood, or other body fluids to identify proteins, genetic
mutations, or chromosomal changes associated with cancer. Each technique
has its own principle, methodology, applications, and advantages.

A. Immunohistochemistry (IHC)

1. Principle

 IHC uses antibodies that specifically bind to target proteins

(antigens) present in tissue samples.
 The antibody–antigen complex is visualized using an enzyme or
fluorescent label that produces a colored reaction under the
microscope.

2. Procedure

1. Tumor tissue is fixed (usually in formalin) and embedded in paraffin.

2. Thin sections are cut and placed on slides.
3. Primary antibodies are applied to bind the target biomarker.
 4. A secondary antibody conjugated to an enzyme (e.g., horseradish
peroxidase) binds to the primary antibody.
5. A chromogenic substrate is added → produces a visible color.

3. Applications

 Diagnosis: Determines tumor type (e.g., S-100 for melanoma,

cytokeratin for carcinoma).
 Prognosis: Ki-67 staining measures cell proliferation.
 Therapy Guidance: Detects HER2, PD-L1, ER, and PR expression for
targeted therapy selection.

4. Advantages

 Visualizes biomarker location within tissue architecture.

 Widely available, cost-effective.

5. Limitations

 Requires adequate tissue sample.

 Interpretation can be subjective.
 Limited to protein detection; cannot detect gene mutations.

B. Fluorescence In Situ Hybridization (FISH)

1. Principle

 FISH detects specific DNA sequences or chromosomal abnormalities

using fluorescent probes that bind to complementary DNA in cells.

2. Procedure

1. Fluorescently labeled DNA probes are prepared.

2. Probes are applied to tumor cell nuclei fixed on slides.
 3. Probes hybridize to target DNA sequences.
4. Under a fluorescence microscope, signals are visualized (colored dots).

3. Applications

 HER2 amplification detection in breast and esophageal cancers.

 ALK or ROS1 rearrangement detection in lung cancer.
 Chromosomal abnormalities in hematological malignancies.

4. Advantages

 Highly specific and sensitive.

 Detects copy number changes and gene rearrangements.

5. Limitations

 Requires specialized equipment.

 Time-consuming and more expensive than IHC.
 Limited to known genetic targets.

C. Polymerase Chain Reaction (PCR)

1. Principle

 PCR amplifies specific DNA sequences to detect mutations or the

presence of viral DNA.

2. Procedure

1. DNA is extracted from tumor tissue or blood.

2. Primers specific to the target gene region are added.
3. Thermal cycling is performed:
o Denaturation → Annealing → Extension.
4. Millions of copies of the target DNA are generated.
 5. Amplified products are analyzed (gel electrophoresis, sequencing).

3. Applications

 Detection of:
o EGFR, KRAS, BRAF mutations (lung, melanoma, colorectal
cancers).
o HPV DNA in cervical/oropharyngeal cancers.
 Quantitative PCR (qPCR) allows measurement of mutation load.

4. Advantages

 High sensitivity (detects mutations in very small samples).

 Rapid and cost-effective for known mutations.

5. Limitations

 Can only detect specific preselected mutations.

 Cannot analyze complex or unknown genetic alterations.

D. Next-Generation Sequencing (NGS)

1. Principle

 NGS allows simultaneous sequencing of millions of DNA fragments,

enabling a comprehensive analysis of multiple genes.

2. Procedure

1. DNA or RNA is fragmented and prepared into a sequencing library.

2. Fragments are amplified and sequenced using high-throughput
platforms.
3. Bioinformatics tools analyze mutations, insertions, deletions, fusions,
and copy number changes.
3. Applications

 Comprehensive genomic profiling:

o Detects hundreds of mutations (BRAF, EGFR, ALK, TP53, etc.).
o Identifies novel or rare genetic variants.
 Helps in selecting targeted therapies and immunotherapies.

4. Advantages

 Broad analysis: Multiple genes in one test.

 Detects both common and rare alterations.
 Essential for precision oncology.

5. Limitations

 More expensive and technically complex.

 Requires advanced data analysis.
 Longer turnaround time compared to PCR.

E. Liquid Biopsy

1. Principle

 Liquid biopsy analyzes tumor-derived material in blood or other

fluids:
o Circulating tumor DNA (ctDNA)
o Circulating tumor cells (CTCs)
o Exosomes, microRNAs.

2. Procedure

1. Blood is collected.
2. Plasma is separated and analyzed for ctDNA using PCR or NGS.
3. Mutations and tumor burden are assessed.
3. Applications

 Non-invasive monitoring of cancer.

 Detects:
o Minimal residual disease (MRD) after treatment.
o Emerging resistance mutations (e.g., EGFR T790M in lung cancer).
 Suitable for patients who cannot undergo tissue biopsy.

4. Advantages

 Minimally invasive.
 Allows real-time tracking of tumor evolution.
 Useful for repeated monitoring during therapy.

5. Limitations

 Lower sensitivity for early-stage cancers (less ctDNA).

 May not detect all mutations if tumor shedding is low.

Advantages of Biomarkers in Cancer Diagnosis

 Enable earlier detection than imaging.

 Provide molecular-level precision for classification.
 Identify patients eligible for personalized therapy.
 Allow dynamic monitoring rather than relying only on static imaging.

Limitations and Challenges

 Not universally specific: Some biomarkers are also elevated in non-

malignant conditions.
 Tumor heterogeneity: A single biopsy may not represent all molecular
features.
 Cost and accessibility: Advanced tests may not be available everywhere.
 Validation required: Many experimental biomarkers are still under
clinical trials.